Endogenously generated Dutch-type Aβ nonfibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammation

Emilie L. Castranio[1], Merina Varghese[2,6,7], Elentina K. Argyrousi[3], Kuldeep Tripathi[4], Linda Söderberg[5], Erin Bresnahan[6,7,8], David Lerner[6,7], Francesca Garretti[6,7], Hong Zhang[3], Jonathan van de Loo[3], Cheryl D. Stimpson[9,10], Ronan Talty[6,7,11], Charles Glabe[12], Efrat Levy[13], Minghui Wang[14], Marjan Ilkov[14], Bin Zhang[14], Lars Lannfelt[3], Brigitte Guérin[15], William D. Lubell[16], Shai Rahimipour[4], Dara L. Dickstein[6,7,9,10], Sam Gandy[1,7,17,18]†, Ottavio Arancio[3]†, and Michelle E. Ehrlich[1,13,19,*]†

[1]Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

[2]George & Anne Ryan Institute for Neuroscience, University of Rhode Island, RI, 02881, USA.

[3]Department of Pathology and Cell Biology, Department of Medicine, and The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, 10032, USA.

[4]Bar-Ilan University, Department of Chemistry, Ramat Gan, 5290002 Israel.

[5]BioArctic, Stockholm, SE-112 51 Sweden

[6]Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

[7]Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

[8]Department of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

[9]Department of Pathology, Uniformed Services University of Health Sciences, Bethesda, MD, 20814, USA.

[10]Henry M. Jackson Foundation for the Advancement of Military Medicine Inc, Bethesda, MD, 20817, USA.

[11]Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

[12]Department of Molecular Biology and Biochemistry, University of California, Irvine, CA, 92697, USA.

[13]Center for Dementia Research, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, 10962, USA, and New York University Grossman School of Medicine, NYU Langone Medical Center, New York, NY, 10016, USA.

[14]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

[15]Department of Radiochemistry, University of Sherbrooke, Sherbrooke, Quebec, J1K 2R1, Canada

[16]Department of Chemistry, University of Montreal, Montreal, Quebec, H3C 3J7, Canada

[17]Department of Psychiatry and Alzheimer's Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

[18]James J Peters VA Medical Center, Bronx, NY, 10468, USA.

[19]Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

† Contributed equally to supervision

* Correspondence: michelle.ehrlich@mssm.edu

Abstract (139 words)

APP^{E693Q} transgenic mice develop aging-related learning deficits and accumulate endogenously generated nonfibrillar aggregates of Aβ (NFA-Aβ) and APP α-carboxy terminal fragments. The *APP*^{E693Q} mutation disrupts amyloid fibril formation, and no plaques develop in these mice. In the current study, the aging-related accumulation of NFA-Aβ in *APP*^{E693Q} mice was revealed by A11 immunohistochemistry and NFA-Aβ-detecting cyclic D,L-α-peptide-FITC microscopy. The presynaptic termini of *APP*^{E693Q} mice developed aging-related physiological abnormalities in post-tetanic potentiation, synaptic fatigue, and synaptic vesicle replenishment. Single-cell RNA sequencing showed that excitatory neurons exhibited the most altered transcriptomic profile, especially involving "protein translation" and "oxidative phosphorylation". Direct measurements of electron transport chain catalysis revealed reduction in mitochondrial complex I activity in Dutch mice. Microglial transcript analysis revealed no evidence of inflammation. The depletion or neutralization of both fibrillar and NFA-Aβ may be needed for complete elimination of Aβ toxicity.

Teaser

APP^{E693Q} "NFA-Aβ only" mice reveal clinically relevant mechanisms despite the absence of detectable inflammation

Introduction

Synaptic dysfunction is believed to be a key pathological hallmark of Alzheimer's disease (AD) that begins gradually and parallels clinical cognitive decline (*1-4*). Many studies have demonstrated that the burden of fibrillar amyloid-β (Aβ) proteinopathy does not correlate with synaptic loss (*5-7*) or with cognitive status(*8*). Instead, some investigators have proposed that brain levels of synaptotoxic nonfibrillar aggregates of Aβ (NFA-Aβ) including Aβ oligomers and protofibrils correlate more closely with synaptic loss (*9, 10*). Synaptic NFA-Aβ has been detected in AD brains, and NFA-Aβ levels in human brain synaptosomes can differentiate subjects with early AD from cognitively intact controls with AD pathology (*11-13*). *In vitro*, synthetic NFA-Aβ peptides can cause inhibition of long-term potentiation (LTP) in hippocampal slices (*14, 15*), while *in vivo* injections of NFA-Aβ into the cerebral ventricles of healthy rats leads to cognitive deficits (*16*). Studies using a transgenic mouse model of AD have demonstrated that neuronal loss in the hippocampus correlates with NFA-Aβ levels but not with amyloid plaque burden (*17*). In 2010, we reported a transgenic mouse model overexpressing Dutch mutant human amyloid precursor protein (*APP*^{E693Q}) on the pan-neuronal Thy1 promoter (*18*). This mutation within the Aβ domain substitutes a glutamine for glutamic acid, thereby disrupting fibril assembly and favoring the formation of NFA-Aβ. The *APP*^{E693Q} mutation causes hereditary cerebral hemorrhage with amyloidosis - Dutch type (HCHWAD) (*19*). The neuropathology of HCHWAD shows prominent cerebrovascular amyloidosis and hemorrhage as well as diffuse parenchymal Aβ deposition (*20*). Although the *APP*^{E693Q} (or "Dutch") transgenic mouse failed to recapitulate the full neuropathology of either AD or HCHWAD, we were struck by the aging-related development

of learning behavior impairment that was observed in the absence of detectable fibrillar Aβ. Analysis of the Dutch mouse brain revealed that this learning behavior impairment was directly related to the brain levels of NFA-Aβ (*18, 21*), an observation supported by imaging data in the current paper using epitomic histochemistry with anti-prefibrillar oligomer-specific antibody A11 (*97*) and NFA-Aβ-detecting cyclic peptide-FITC fluorescence microscopy (*22*). The Dutch mice also exhibit detectable cerebrovascular Aβ deposition and traces of perivascular iron (presumably due to the extravasation of red blood cells) without overt hemorrhage. The reported accumulation of APP α- and β-carboxyl-terminal fragments (APP-CTFs) in the Dutch mouse brain has raised the possibility that the learning impairment might be at least partially attributable to APP-CTF proteinopathy alone or in combination with the NFA-Aβ proteinopathy (*23*).

A detailed study of hippocampal CA1 neurons reported that significant decreases in dendritic length and complexities of apical, but not basal, dendrites were observed in Dutch compared to wildtype mice (*24*). The synaptic ultrastructure in the same brain region revealed no differences in overall synaptic density or morphology. A significant reduction in the postsynaptic density (PSD) length of synapses was identified on mushroom spines in Dutch mice compared to those of wildtype littermates. In the current study, electrophysiological and immuno-electron microscopy approaches were employed to investigate the excitatory synapses in the hippocampus of the Dutch mouse.

Bulk sequencing of RNA from the entorhinal cortex and dentate gyrus of Dutch mice revealed entorhinal cortex profiles that correlated with several human late-onset AD signatures (*25*). Microglial signatures were enriched in the differentially expressed genes (DEGs). Differential exon usage was also prominent in the Dutch mouse entorhinal cortex and the PSAPP ($APP^{KM670/671NL}/PSEN1^{\Delta exon9}$) mouse dentate gyrus. The transcriptomes from the entorhinal cortex and the dentate gyrus of Dutch mice were also enriched in markers of glutamatergic neurons, synaptic transmission, and protein translation. To study transcriptomics in the Dutch mouse hippocampus, single-cell RNA sequencing (scRNA-seq) was employed and revealed dysregulation of pathways for protein translation, oxidative phosphorylation, and the electron transport chain. Direct measurements of electron transport chain catalysis revealed changes in activity of mitochondrial complex I but not in that of complexes II, III, or IV.

In summary, a multi-disciplinary analysis of the Dutch mouse has now revealed alterations in synaptic physiology, gene expression, and protein translation in excitatory neurons, as well as changes in the transcriptomic profile and mitochondrial morphology and activity. Moreover, the high sensitivity of scRNA-seq has enabled neuroinflammation to be ruled out as a major contributor to pathogenesis in the hippocampi of Dutch mice. The present studies are among few focusing on endogenous generation of NFA-Aβ without the concurrent presence of potential confounds from either Aβ fibrils or synthetic peptides. These findings support the notion that fibrillar Aβ is not necessary for the aging-related learning deficit observed in Dutch mice. These data may have important

implications for the genesis of cognitive impairment in humans. The clinical response to anti-amyloid antibody therapy may be dampened due to the persistence of toxic NFA-Aβ conformers that go undetected in contemporary analysis of fluid biomarkers and in amyloid fibril positron emission tomography (PET) imaging. Depletion or neutralization of NFA-Aβ may be required for complete elimination of clinically relevant Aβ toxicity.

Results

Dutch mice show increased levels of nonfibrillar aggregate with aging.

Aging-dependent investigation of the Dutch mice revealed that 12 months is the first age at which deficits attributable to NFA-Aβ can be detected (*18*). To determine the involvement of NFA-Aβ in brain changes, multiple analyses were conducted at different ages, before and after the appearance of NFA-Aβ. Epitomic characterization was performed on cortical tissue from 2- and 24-month-old Dutch mice. Interestingly, this characterization revealed a significant increase with aging in the A11/6E10 ratio (ratio of prefibrillar oligomer content to total Aβ content; $F(3,16) = 17.05$; $p < 0.0001$), but no such aging-related change in the OC/6E10 ratio (ratio of fibrillar oligomer content to total Aβ content; $F(3,16) = 2.557$; $p = 0.0916$) in Dutch mice (**Figure 1, Supplementary Figure 1A**). Furthermore, brains were analyzed for the presence of protofibrils (PF) using the homogenization protocol described in Tucker *et al.* (*26*) and assayed for PF levels in the TBS soluble fraction using a mAb158-mAb158 sandwich MSD assay employing an in-house synthetic protofibril as calibrator. Both assays showed very low levels of Aβ PF. In the mAb158 sandwich assay, Aβ PF levels were around 100 pM, levels indistinguishable from those in homogenates of wildtype mice (**Supplementary Figure 1B**). No PF were detected in the cerebellum. Levels of PF in Dutch mice were approximately 10- to 100-fold lower than those measured in Tg-APP^{ArcSwe} and Tg2576 (depending on age analyzed). In addition, $A\beta_{38/40/42}$ fragments were analyzed in the TBS insoluble pellet fraction after dissolution in formic acid and neutralization. Levels of Aβ PF were again very low, consistent with the absence of parenchymal plaques in Dutch mice.

The elevation of NFA-Aβ levels in the cortex, thalamus, and hippocampus of Dutch mice was visually and morphologically confirmed using a combination of immunohistochemistry using A11 antibody and fluorescence microscopy employing cyclic D,L-α-peptide-2 (CP-2)-FITC as a fluorescein-tagged NFA-Aβ-detecting ligand (*22*) (**Figure 1, Supplementary Figures 1C and 2-3**). The hypothesis that CP-2 and A11 bind to similar or identical domains on NFA-Aβ was confirmed by cross-competition blocking experiments in which pre-incubation of brain slices with CP-2 peptide prevented the subsequent binding of the prefibrillar oligomer-specific antibody A11 (**Supplementary Figure 4**). Furthermore, the interaction of CP-2 with NFA-Aβ has been characterized (*99-103*): CP-2 was demonstrated (1) to stabilize Aβ dimers and trimers using a photoinduced cross-linking of unmodified proteins (PICUP) assay (*99-102*) and (2) to bind 10 nm particles typical of NFA-Aβ (*103*). In the

current study, CP-2 exhibited similar K_d values for both fibrillar and nonfibrillar forms of Aβ in surface plasmon resonance (SPR) assays (**Supplementary Methods**): CP-2 interacted with Aβ fibrils and NFA-Aβ with K_d values of 6 and 4 μM, respectively.

Dutch mice showed no significant impairment in basal synaptic transmission and long-term synaptic plasticity in the hippocampus.

The relationship between synaptic input strength and the resulting electrical response, the so-called "input-output relation" and long-term potentiation (LTP) were tested in 7- to 7.5-month-old and 10.5- to 11-month-old Dutch mice. The two genotypes displayed similar input-output relationships and LTP in both age groups, suggesting that basal synaptic transmission at the CA1 region of the hippocampus and long-term synaptic plasticity at the Schaffer collateral were unimpaired in Dutch mice **(Figure 2)**.

Dutch mice showed no change of hippocampal mGluR-2/3 expression or of mGluR-2/3+ synapse density.

Comparable levels of mGluR-2/3 protein were observed in Western blots of the insoluble membrane fraction from the hippocampus of 12-month-old wildtype and Dutch mice (**Supplementary Figure 5A**). Since Western blots may not detect regional differences, array tomography and immunofluorescence were used to analyze mGluR-2/3 puncta after staining serial sections of CA1 neurons with Neurotrace (**Supplementary Figure 5B**). Comparable densities in the CA1 of wildtype and Dutch mice were observed in 3D reconstructions of mGluR-2/3 synaptic puncta by array tomography (**Supplementary Figure 5C**, $F_{(4,3)} = 1.476$, $p = 0.7802$). Quantification of the total mGluR-2/3 puncta output yielded an average tissue density (puncta/μm^3) of 0.275 ± 0.087 for wildtype mice and 0.322 ± 0.112 for Dutch mice. Both genotypes exhibited comparable puncta size ranges, and no significant difference in average mGluR-2/3 puncta size (**Supplementary Figure 5D**; $F_{(1,3)} = 0.751$, $p = 0.538$) per percentile per sample. Similarly, neither the density nor size of GluN1 puncta were altered in Dutch mice (**Supplementary Figure 5E-F**; $F_{(4,3)} = 1.431$, $p = 0.8003$ for density and $F_{(1,3)} = 0.116$, $p = 0.950$ for puncta size).

Dutch mice had larger PSD area on small mGluR-2/3$^+$ synapses in the CA1 region.

Changes in mGluR-2/3$^+$ excitatory neurons were examined at the ultrastructural level in 12-month-old mice. Comparable percentages of mGluR-2/3$^+$ synapses among total, non-perforated, and perforated synapses in the CA1 were observed in Dutch and wildtype mice using immunogold EM against mGluR-2/3 (**Figure 3A-C**). Moreover, Dutch and wildtype mice exhibited no difference in the total and perforated synapses (**Figure 3D, F**). Higher postsynaptic density (PSD) area of non-perforated mGluR-2/3$^+$ synapses was detected in the Dutch

65 compared to wildtype mice (**Figure 3E**), both of which had comparable distributions of mGluR-2/3^{+} particles per
66 PSD area (**Figure 3G-I**).
67
68 ***Dutch mice exhibited defects in PTP, SF, and replenishment of the vesicle pool after depletion.***
69 We assessed several mechanisms related to function of the presynaptic terminal. 11- to 13-month-old Dutch
70 mice and their wildtype littermates showed the same response in paired-pulse facilitation (PPF) **(Figure 4A)**, a
71 type of short-term plasticity that is most likely dependent upon the build-up of Ca^{2+} in the presynaptic neuron due
72 to the close pairing of two action potentials. Accumulation of Ca^{2+} in the presynaptic neuron results in increased
73 neurotransmitter release and subsequently increased response after the arrival of the second action potential(*27*).
74 Accordingly, facilitation is no longer present when a long-time interval (1 second) is introduced between the two
75 stimuli. Both wildtype and Dutch mice showed increased facilitation at short time intervals, and no difference was
76 observed between the two genotypes. In contrast to PPF, Dutch mice showed decreased post-tetanic potentiation
77 (PTP) when compared to wildtype mice **(Figure 4B)**. PTP is performed in the presence of D-2-amino-5-
78 phosphonovalerate (D-APV) that blocks NMDA receptors, thereby preventing the onset of plasticity through
79 NMDA-dependent postsynaptic mechanisms that might interfere with its measurement. Due to the DAPV, the
80 fEPSP slope declines back to baseline a few seconds after stimulation. PTP is another form of short-term plasticity
81 and reflects the enhanced release of neurotransmitter due to the increased levels of Ca^{2+} at the presynaptic terminal
82 during the tetanic stimulation(*28*).
83 We also studied the effect of the Dutch mutation on the efficacy of presynaptic mechanisms by examining
84 synaptic fatigue (SF) and replenishment of the vesicle pool after its depletion. Both mechanisms appeared to differ
85 between wildtype and Dutch mice. Specifically, the rate of decay examined with SF was faster for the Dutch mice
86 as compared to wildtype **(Figure 4C),** whereas the growth rate during the replenishment phase was higher in the
87 Dutch in comparison to wildtype **(Figure 4D).** The decline in the slope that is observed during SF is thought to
88 represent the depletion of the readily releasable pool (RRP) of neurotransmitter that resides in vesicles at the
89 presynaptic cells, while replenishment depicts the refilling process of the RRP after its depletion with high
90 frequency stimulation. Mechanistically, it has been suggested that both SF and replenishment are dependent on
91 accumulation of residual Ca^{2+} at the presynaptic terminal(*27, 28*).
92
93 ***Dutch mice exhibited no change in vesicle size or number of docked vesicles but show a trend towards fewer***
94 ***vesicles in the reserve pool at presynaptic terminals in the CA1.***
95 The size, number, and distribution of vesicles were quantified within the presynaptic terminal of 12-month-
96 old mice. No differences were observed in synaptic vesicle sizes at the presynaptic terminal nor the number of
97 docked vesicles at the synapses of the active zone in Dutch and wildtype mice (**Supplemental Figure 6A-C, E,**

98 **G**). A decline in the number of synaptic vesicles was found in the reserve pool beyond 300 nm from the active
99 zone of Dutch compared to wildtype mice, but did not reach statistical significance and appeared to be driven by
00 vesicles in large synapses (**Supplemental Figures 6D and 6H**). The hippocampi of Dutch and wildtype mice
01 exhibited no differences in the levels of either the postsynaptic density protein of 95kDa (PSD95) or the
02 presynaptic marker synaptophysin (**Supplemental Figure 7**).
03
04 ***Dutch mice had no change in synaptic distribution of mGluR-2/3+ in the CA1.***
05 Comparable distributions of mGluR-2/3 were observed by immunogold labeling and electron microscopy
06 (EM) at the synapse (**Figures 5A-C**), pre- and postsynaptic compartments (**Figure 5D**), presynaptic active zone,
07 synaptic cleft, peri-synaptic area, postsynaptic membrane, and postsynaptic cytoplasm (**Figure 5E**) in 12-month-
08 old wildtype and Dutch mice.
09
10 ***Dutch mice display shared gene expression profiles across multiple cell types.***
11 Employing brains from Dutch mice alongside sex- and age-matched wildtype littermates, scRNA-seq was
12 performed. Hippocampi were collected from mice at 12 months, an age characterized by established cognitive
13 deficits and high levels of NFA-Aβ and α-CTF in Dutch mice(*18*). After quality control filtering (**Supplementary**
14 **Figure 8**), 61,642 (32,661 Dutch and 28,981 wildtype) cells were isolated from thirteen distinct clusters which
15 were identified based on the expression of well-known cell-type-specific markers **(Figure 6A-B**, **Supplementary**
16 **Tables 1-2).** Pseudo-bulk differential expression analysis was used to identify gene expression changes within
17 each cell type. For further analysis (C0-6), clusters of interest were identified based on differentially expressed
18 genes (DEGs; adj. p-value cutoff <0.05) (**Figure 6C-D**, **Supplementary Figures 9-12, Supplementary Table**
19 **3**).
20 Faced with considerable overlap in DEGs, the clusterProfiler(*29*) approach was employed to compare
21 biological themes and identify the Gene Ontology (GO) term enrichment shared among the gene clusters. Among
22 the shared terms were "structural constituent of ribosome" (example genes include: *Rpl23, Rpl30, Rpl37a, Rpl6,*
23 *Rpl9, Rps24*) **(Figure 7A-B)**, and "amyloid-beta binding" (*Apoe, Atp1a3, Clu, Cst3)* **(Figure 7A, C)**. The shared
24 DEGs and GO terms across clusters were similar to a previously identified "aging signature" in mouse brain(*30*),
25 in which ribosomal protein genes, long noncoding RNA genes (e.g., *Malat1*) as well as ribosome-related pathways
26 and processes, all were significantly affected in 21- to 22-month-old mouse brain across multiple cell types
27 compared to that of their 2-to 3-month-old counterparts. Across clusters, 453 DEGs were found to overlap with
28 the aging-related gene list **(Figure 7D)**, from which 435 genes displayed the same directionality across all clusters
29 (389 upregulated and 46 downregulated, **Figure 7E**) as reported.(*30*).
30

Dutch mice do not show obvious differences in microglial gene expression.

In many Aβ-depositing mouse models of AD, microglia show prominent transcriptional responses and increased microgliosis with conspicuous peri-plaque localization(*31, 32*). Additionally, the microglial immune response to NFA-Aβ has been implicated as an early, key step in AD pathogenesis. To investigate the microglial responses in more detail, we performed subclustering analysis, which revealed three subpopulations of microglia in the hippocampus (**Figure 8A**). None of the subpopulations showed higher abundance in either genotype. The subpopulations also did not segregate based on expression of established microglial profile markers, such as homeostatic, disease-associated microglia (DAM)(*33*), type I interferon-induced (IFN), or major histocompatibility complex-expressing (MHC) signatures(*34*) (**Figure 8B**). Expression of homeostatic markers was high in all microglia subpopulations and did not change in microglia from the hippocampus of Dutch mice (**Figure 8C**). Additionally, no differences were seen in IBA1 IHC between 12-month-old Dutch and wildtype mice **(Supplementary Figure 13A-B)**. Notably, we also did not find an increase in colocalization of C1q and PSD95 puncta in 12-month-old Dutch mice **(Supplementary Figure 13C)**, as was reported in J20 mice(*35*).

Dutch mice show changes in gene expression associated with translation in excitatory neurons.

Cluster 6 was identified as excitatory neurons and showed the most extensive and unique transcriptional response in Dutch mice (**Figure 6C-D, Figure 9A**). In the GO term analysis, upregulated Cluster 6 DEGs included "cytoplasmic translation" (*Eif2s2, Eef1a1, Eef1b2, Rpl22, Rpl26, Rpl27*) and "negative regulation of amyloid fibril formation" (*Cryab, Pfdn6, Slc25a4, Grin2b, Stmn1, Smad4, Pik3r1*) **(Figure 9B, Supplementary Table 4).** Notably, "regulation of synapse organization" was also among the top GO terms (*Cask, Cdh8, Gpc4, Grin2b, Mef2c, Nrxn1, Pafah1b1, Ptprd, Tuba1a, Ube2v2, Malat1, Opa1, Mycbp2, Nrcam, Il1rapl1, Arhgef9*), a selection of which are also highlighted in **Figure 9A**. In the GO term analysis, downregulated Cluster 6 DEGs included those related to processes associated with mitochondrial bioenergetic function, i.e., "electron transport chain" (*Mt-Co1, Mt-Co3, Mt-Cytb, Ppp1cb, Calm2*) and "oxidative phosphorylation" (*mt-Atp6, mt-Nd1, mt-Nd3)* (**Figure 9C, Supplementary Table 5**). A selection of unique DEGs from Cluster 6 is shown in **Figure 9D.**

Gene expression was also examined for biological processes associated with presynaptic mechanisms and synaptic transmission, specifically "regulation of synapse organization", a subset of "regulation of cell morphogenesis" (**Supplementary Figure 14A**). Myocyte Enhancer Factor 2C (*Mef2c*) is among this gene list and has been identified as a candidate risk gene for developing late onset Alzheimer's disease (LOAD)(*36, 37*). Considering that oligodendrocytes can modulate presynaptic properties and synaptic transmission(*38, 39*), relevant biological processes such as "modulation of chemical synaptic transmission" were assessed and found among the top biological processes in Cluster 4 oligodendrocytes (**Supplementary Figure 14B, Supplementary Table 6)**. Approximately 25% of the genes present in this biological process are among DEGs in Cluster 6. Genes

associated with synaptic transmission that were among those specific to Cluster 4 included transferrin (*Trf),* a recently identified biomarker of AD(*40*), and carbonic anhydrase 2 (*Car2*). Carbonic anhydrase inhibitors have been considered for prevention of neurovascular dysfunction in CAA and AD due in part to their ability to prevent mitochondrial dysfunction and oxidative stress (*41, 42*).

A cell-cell communication analysis was performed using the software tool Cellphone DB to compute interactions between clusters based on the known Ligand-Receptor (LR) pairs (**Supplementary Table 7**). For each LR in each sample, the software estimated the interaction strength from Cluster 4 oligodendrocytes to Cluster 6 excitatory neurons, from which differences in interaction strengths between Dutch and WT mice were evaluated by t-test. Twelve LR pairs showed significant interaction difference at p-value ≤ 0.05, and all twelve presented higher interactions in Dutch mice. Among these LRs, *Gabbr2* was up-regulated in the Cluster 6 excitatory neurons in Dutch mice compared to those of wildtype (log2FC = 0.19, adj. p-value = 3.6E-4). In Dutch compared to wildtype mice, stronger interactions were exhibited by *Gabbr2* with multiple GABA inhibitory neurotransmitter complex partners including GAD2, SLC6A11, SLC6A1, SLC6A8, SLC6A6, and SLC32A1.

Dutch mice have fewer and smaller mitochondria in CA1 presynaptic boutons.

The number and morphology of mitochondria were assessed in the presynaptic terminals of excitatory neurons in the *stratum radiatum* of wildtype and Dutch mice (**Figure 10A, B**). Previously, NFA-Aβ has been reported to cause imbalance in mitochondrial fission-fusion, leading to fragmented morphology and altered function(*43-47*). Fewer presynaptic mitochondria were found in Dutch compared to wildtype mice (**Figure 10C**, mean ± SD for total of mitochondria per presynaptic bouton = 106.3 ± 20.06 in wildtype and 75.60 ± 14.62 in Dutch, p= 0.0324 by two-tailed unpaired t test). This deficiency in the Dutch mice was likely due to fewer straight mitochondria at the presynaptic terminals, because curved mitochondria numbers were unchanged between genotypes (**Figure 10D-F**, mean ± SD for number of straight mitochondria = 101.3 ± 17.95 in wildtype and 71.80 ± 15.06 in Dutch, p= 0.314 by two-tailed unpaired t test. Mean ± SD for number of curved mitochondria = 5.00 ± 2.16 in wildtype and 3.80 ± 2.59 in Dutch). In assessments of differences in morphology, mitochondrial diameters were comparable (**Figure 10G**, mean ± SD = 328.6 ± 19.29 in wildtype and 301.8 ± 28.73 in Dutch), but shorter lengths were found in 12-month-old Dutch compared to wildtype mice, as estimated from the number of layers traversed in the consecutive sections by each mitochondrion (**Figure 10H**). Each layer traversed was ~ 80 nm using 3-dimensional reconstruction of measurements from serial sections.

Dutch mice have reduced mitochondrial electron transport chain complex I activity.

The activities of electron transport chain complexes I-IV and citrate synthase were assessed in hippocampi from 7- and 12-month-old wildtype and Dutch mice as described(*104, 105*). Each complex activity was

97 standardized to either μg protein (p=0.0355) or to mU/ml of citrate synthase (CS) and analyzed using an unpaired
98 t test (p=0.0197) (**Supplemental Figure S15, Supplemental Tables 8, 9**). Compared to that of wildtype,
99 mitochondrial complex I activity was reduced in 12- but not 7-month-old Dutch mice.
00

01 **Discussion**

02 The purpose of this study was to elucidate the molecular pathogenesis underlying the learning behavioral
03 deficits exhibited by the Dutch mouse model which accumulates NFA-Aβ and APP α-CTFs but never forms
04 amyloid fibrils. Our study adds to the few that have detected endogenously generated NFA-Aβ without concurrent
05 presence of fibrils or the presence of synthetic peptides. The location of Dutch NFA-Aβ in the mouse brain was
06 ascertained using immunohistochemistry with A11 antibody and fluorescence microscopy with a cyclic peptide-
07 FITC ligand(*22*). In contrast to the apparently normal density and morphology of synapses in excitatory neurons,
08 we observed abnormalities in the apical dendrite structure in the CA1 of Dutch mice(*24*). Therefore, we sought
09 to determine whether Dutch mice exhibit plasticity impairment during growth from 7 to 13 months, before and
10 after NFA-Aβ aggregation can be detected in the brain. A variety of electrophysiological techniques were used to
11 examine short- and long-term synaptic plasticity. Although no changes in basal synaptic transmission nor long-
12 term synaptic plasticity were observed at the CA1-CA3 area of the hippocampus in slices obtained from young
13 (7- to 7.5-month-old) and old (10.5- to 11-month-old) Dutch mice, impaired short-term synaptic plasticity
14 developed at the CA1-CA3 synapses first appearing at the age of 11 to 13 months.

15 Assessment of the I-O curve and the LTP response after high frequency stimulation in the CA1-CA3 synapses,
16 indicated no difference between Dutch and wildtype genotypes, suggesting that NFA-Aβ and/or APP α-CTFs
17 affect neither spontaneous activity nor the long-term plasticity in the examined age window. In contrast,
18 intracerebroventricular injection of synthetic Dutch and Arctic (APP^{E693G}) Aβ peptides have been previously
19 reported to block LTP in rats(*48*). Long-term plasticity changes may possibly be manifested only in older Dutch
20 mice. In addition, changes may occur in other types of long-term synaptic plasticity such as long-term depression,
21 as well as in other areas of the hippocampus, such as mossy fiber-CA3 synapses. Despite normal *long-term*
22 synaptic plasticity in young or old Dutch mice, defects in several types of *short-term* plasticity emerged in the
23 aging 11- to 13-month-old Dutch mice. Specifically, mice carrying the Dutch mutation exhibited impaired PTP,
24 synaptic fatigue (SF), and impaired replenishment of the synaptic pool, but unaffected PPF. Both PPF and PTP
25 are related to accumulation of Ca^{2+} at the presynaptic terminal, due (respectively) to two closely paired pulses or
26 to high frequency stimulation, both of which augment neurotransmitter release. Although impaired PTP without
27 changes in PPF might seem contradictory, previous studies have shown that PPF and PTP are governed by
28 different synaptic vesicle proteins. Specifically, the absence of the synaptic vesicle protein synaptogyrin I in mice

causes impaired PTP, but its absence has no effect on PPF(*49*). More in-depth investigation of synaptic vesicle proteins is required to elucidate the molecular mechanisms underlying impaired plasticity in Dutch mice.

Our earlier studies identified abnormalities in the dendritic structure of excitatory neurons in the CA1 of Dutch mice(*24*). Although mGluR2 is necessary for synaptic binding of oAβ, and mGluR3 has been reported to mediate the effects of NFA-Aβ on synaptic function (*50, 51*), the CA1 of Dutch and wildtype mice exhibited similar synaptic density of mGluR-2/3^{+}. Moreover, similar levels of mGluR-2/3 were observed in the hippocampus as well as the pre- and postsynaptic compartments of axospinous synapses in the CA1 of Dutch and wildtype mice. In contrast, mGluR-2/3 expression was previously reported to be reduced in the CA1 of AD patients(*52, 53*), depending on which hippocampal subfield was examined(*53, 54*). Furthermore, in primary rat neurons treated with NFA-Aβ, mGluR-2/3 levels initially increased as the immediate response but decreased following activation, suggesting that synaptic activity contributes to the effect of NFA-Aβ on receptor subunit expression (*55*). In CA1 synapses in the Dutch mice, differences were identified in the greater PSD area of small mGluR-2/3^{+} synapses and in the reduced number and size of presynaptic mitochondria (discussed below in the context of the transcriptomic data). Recruitment of mGluR1 or NMDA receptors to the PSD in the presence of NFA-Aβ could be a possible explanation for our finding of increased PSD area on non-perforated mGluR-2/3^{+} synapses in the Dutch mice.

Dutch mice showed altered presynaptic plasticity mechanisms related to the RRP of neurotransmitters. Specifically, Dutch mice exhibited respectively faster rates of decay and recovery during high frequency stimulation that causes fatigue at the synapses and after synaptic depression. The depletion and replenishment of the RRP of neurotransmitters appear more profound in Dutch mice in comparison to wildtype mice. The RRP of neurotransmitters refers to a small subset of neurotransmitter-containing vesicles residing close to the presynaptic terminal (either docked or non-docked) and disposed for immediate released during stimulation. Besides accumulation of Ca^{2+}, several parameters could affect the decay of the RRP including the number of active zones and the number of docking sites at the presynaptic terminal. In turn, replenishment of the RRP could be mediated by the Ca^{2+}-mediated recruitment of vesicles from the reserve pool to the RRP. The detailed mechanism of the observed changes in the RRP of neurotransmitter requires further investigation.

The required interplay between pre- and postsynaptic neurons during synaptic plasticity suggests that presynaptic changes could affect activation of postsynaptic neurons eventually leading to long-term synaptic impairments. Despite the observed changes in the release probability and the RRP of neurotransmitters, high-frequency stimulation resulted in normal LTP, suggesting that Dutch mice do not display derangement of postsynaptic mechanisms at the ages studied, an observation that could be attributed to compensatory mechanisms. In one possibility, the decrease in release probability with PTP may be balanced by the increased depletion and replenishment of the RRP.

62 In contrast to previous reports, hippocampal microglia (Cluster 2) did not show a high number of DEGs, nor
63 were differences in expression of microglia DAM and homeostatic signatures observed between Dutch and
64 wildtype mice. The highest total and unique number of DEGs were found in excitatory neurons (Cluster 6) and
65 were associated with processes such as "protein translation" and "electron transport chain". Knowing that
66 presynaptic function can be impacted by oligodendrocytes(*38, 39*), and that Cluster 4 had the second highest total
67 number of DEGs, LR pairs were examined between oligodendrocytes and excitatory neurons, which indicated
68 that *Gabbr2* showed stronger interaction with multiple GABA inhibitory neurotransmitter complex partners in
69 Dutch mice.
70 Finally, prior studies using bulk RNAseq on the entorhinal cortex and dentate gyrus of wildtype and Dutch
71 mice were re-examined using scRNA-seq, revealing no obvious differences in microglial transcriptional profiles.
72 Moreover, the Dutch mouse hippocampal transcriptome did not present neuroinflammatory and microglial
73 transcriptomic responses that are commonly observed in models with senile plaques and amyloid fibrils (e.g.,
74 PSAPP, 5XFAD). Failure to capture such a response may be due to the cell populations selected for profiling.
75 Indeed, previous characterization indicated that microgliosis in other Dutch mice (*56*) was not generalized but
76 was limited to the immediate proximity of Aβ-laden vessels. In this study, no differences were observed in
77 microgliosis nor were increases detected in C1q colocalization with PSD95, a process reported to be induced by
78 NFA-Aβ, that drives activation of complement and synapse elimination(*35*). In a transcriptomic analysis on
79 postmortem brain tissue from humans with HCHWAD, inflammatory genes and pathways were also not
80 prominently represented(*57*). As detected in the Dutch mouse, the main pathways over-represented in the human
81 HCHWAD brains were related to mitochondrial dysfunction (*57*). The principal up-regulated pathways entail
82 interactions of the extracellular matrix and transforming growth factor beta signaling. In a clustering analysis to
83 identify molecular subtypes of AD, gene expression profiles have been gleaned from the Mount Sinai Brain Bank
84 (MSBB-AD) and Religious Orders Study-Memory and Aging Project (ROSMAP)(*58*). The Dutch mouse gene
85 signature significantly correlated with the subtype of "typical" or "Aβ predominant" AD presentation, and was
86 characterized by increased immune activation and inflammation, as well as decreased synaptic signaling and
87 dysregulation in neuronal processes and synaptic signaling (*58*). Considering our current results, the overlap
88 between the Dutch model and the AD subtypes may be more closely associated with alterations in synaptic
89 signaling than immune activation. Taken together, the results minimize the contribution of neuroinflammation in
90 the pathogenesis leading to learning disorder in Dutch mice.
91 Among the most dysregulated pathways in the Dutch mouse brain was "structural constituent of ribosome",
92 which is associated with the most significant GO term in Cluster 6 "protein translation". Increasing evidence
93 suggests that dysregulation of mRNA translation contributes to the pathogenesis of several neurological diseases,
94 including AD(*59*). Accumulation of Aβ is linked to increased protein synthesis through loss of interactions from

key translation regulators, particularly translation repressors(*60*). When the cell-type specific transcriptional responses to NFA-Aβ were examined, altered transcriptional profiles were identified in multiple cell types. In these profiles, overlap with GO term enrichment analysis indicated "amyloid-beta binding" among the shared processes. Previously, both DEGs and processes altered in the Dutch mouse were identified in an aging-related signature(*30*), and a recent study revealed that Aβ accumulation triggers fragmentation of the Golgi apparatus, a key organelle needed for protein processing(*61*). A vicious cycle can be created because Golgi fragmentation exacerbates Aβ production(*61*). On the contrary, prevention of the phosphorylation of Golgi structural proteins, such as GRASP65, has rescued apparatus structure and reduced Aβ secretion(*61*).

The Cluster 6 neuron DEGs downregulated in Dutch mice compared to wildtype were associated with mitochondrial functions, specifically GO terms "electron transport chain" and "oxidative phosphorylation". In concordance, cellular respiration pathways were the most significantly altered pathways identified in the transcriptomic analysis from human patients with HCHWAD(*57*). Moreover, fewer and smaller mitochondria were found at the presynaptic terminals of excitatory neurons in the CA1 of Dutch mice compared to wildtype. Strong evidence linking NFA-Aβ to mitochondrial complex I endpoints has come from the combined use of a genetically encoded fluorescent redox sensor and multiphoton microscopy to image and monitor *in vivo* the mitochondrial redox imbalance in neurons from the APP/PS1 transgenic mouse model of AD(*62*). The deposition of Aβ plaque and particularly soluble NFA-Aβ species were shown to lead to increased mitochondrial oxidative stress levels within neuronal mitochondria(*62*). Mitochondrial redox dysregulation in neurons was prevented by inhibition of mitochondrial calcium influx, which is pathologically exacerbated in Aβ plaque-depositing mice(*62*). Furthermore, mitochondria-targeting antioxidants decreased mitochondrial oxidative stress back to basal levels and reverted Aβ plaque-associated dystrophic neurites in the APP/PS1 mice(*62*). Defective mitochondrial complex I activity has been detected in living human AD brain(*63*). Altered mitochondrial fission and fusion has been observed in the hippocampus of human AD and in Tg2576 mice and may explain the observations of decreased mitochondrial density and smaller mitochondria in Dutch mice(*46, 65*). Increased mitochondrial fragmentation has been reported in neurons exposed to NFA-Aβ(*66*). Elevated levels of NFA-Aβ impaired transport of mitochondria in dendrites and axons and increased mitochondrial permeability in mice harboring the Osaka mutation of APP (APP^{E693D})(*72*). Mitochondria-targeting therapy holds promise for treating neurodegenerative disease (*108, 109*) and could be used in combination with other anti-Aβ and anti-tau therapies to arrest AD progression. Our finding of reduced density of presynaptic mitochondria in the CA1 of Dutch mice suggests that NFA-Aβ might also affect transport of mitochondria to axon terminals. The dysfunction of mitochondria and endoplasmic reticulum (ER) protein translation observed in Dutch mice is consistent with observations in other mouse models of AD(*62, 69*).

In conclusion, the current study provides several notable observations. Two independent methods visualized for the first time *endogenously generated* NFA-Aβ *in vivo* in the absence of artefacts related to the intracerebral injection of synthetic peptides or to the concurrent presence of Aβ fibrils. Changes related to the APP^{E693Q}-genotype were revealed in NFA-Aβ histopathology, in expression of mitochondrial and neuronal translation-related genes, in presynaptic physiology, and in the ultrastructure of presynaptic mitochondria. Neuroinflammation is not a major contributor to the pathogenesis in Dutch mice. Neither fibrillar Aβ nor neuroinflammation is required for the aging-related learning behavior phenotype.

This study of APP^{E693Q} mice is particularly timely considering the promising outcome of clinical trials for lecanemab(*70*) and donanemab (*71*). Unlike other anti-amyloid antibodies, lecanemab selectively binds to NFA-Aβ, leading to its neutralization and elimination(*70, 71*). After 18 months of treatment with either antibody, participants experiencing mild cognitive impairment due to AD showed a modest but statistically significant 27% slower rate of cognitive decline with lecanemab and 35% slower rate with donanemab. The modest clinical response to therapeutic infusion of anti-amyloid antibodies may be attributable, at least in part, to the persistence of residual toxic NFA-Aβ that goes undetected by current fluid biomarker analysis and amyloid fibril imaging. The potential clinical importance of NFA-Aβ is reinforced by the recent discovery of a new FAD mutation (APP^{D678N}) that also favors NFA-Aβ accumulation (*72*). Therapeutic depletion of NFA-Aβ may be required for optimum and more robust cognitive benefits from anti-amyloid antibody infusion. Newer methods for imaging NFA-Aβ (e.g., [^{64}Cu]-NOTA cyclic D,L-α-peptides) in the living human brain (*22*) and assays for detection of NFA-Aβ in biofluids (*106, 107, 110*) may provide earlier diagnosis and improved monitoring of patients undergoing Aβ immunodepletion therapy by assuring that both fibrillar and nonfibrillar Aβ conformers are cleared as completely as possible.

Materials and Methods

Experimental animals

Male and female 2- to 24-month-old mice were used in this study. All animals were group housed in microisolator cages under a 24-hour light/dark cycle and given *ad libitum* access to food and water. The Dutch mice used in the study express the human *APP* gene harboring the Dutch mutation (APP^{E693Q}) under control of the *Thy1* promoter(*18*). All animal procedures were conducted in accordance with the National Institute of Health Guidelines for the Care and Use of Experimental Animals and were approved by the Institutional Animal Care and Use Committees at the Icahn School of Medicine at Mount Sinai LA10-00462.

56 *Dot blot assay*

57 The cerebral cortices of mouse brain samples were thawed and lysed by adding 2x volume of lysis buffer
58 [5.0 mM NaCl, 5.0 mM EDTA, 1.0 mM dithiothreitol (DTT), and protease inhibitor mixture in 25 mM Tris
59 buffer, pH 7.5] containing 0.5 mm Zirconium Oxide Beads (ADV-ZrOBO5, ORNAT, Israel), homogenized with
60 a tissue grinder motor pestle (Alex-Red, Israel) on ice, and the mixtures were centrifuged at 4°C at 14,000 rpm
61 for 15 minutes. The total protein in each sample was quantified by Nano-Drop absorbance quantification at 280
62 nm.

63 For dot-blot analysis, equal amounts of samples of diluted proteins (100 ng/μL) were directly applied in
64 duplicate onto nitrocellulose membrane and dried at room temperature for 30 minutes. The membrane was then
65 blocked with 5% bovine serum albumin (BSA) in tris-buffered saline (TBS) (pH 7.4) containing 0.1% (v/v) Tween
66 20 (TBST). Blots were incubated overnight at 4°C with: 6E10 mouse monoclonal antibody (1:1000); rabbit
67 polyclonal antibody recognizing prefibrillar oligomers, A11 (1:5000); rabbit monoclonal antibody OC
68 recognizing fibrillar oligomers (1:1000); anti-murine-α-tubulin antibody (1:5000) in TBST containing 5% BSA.
69 The membranes were washed with TBST three times and incubated for 1 hour at room temperature with
70 horseradish peroxidase (HRP) conjugated either to an anti-mouse IgG (1:10000) or anti-rabbit IgG (1:5000) in
71 5% BSA in TBST. The blots were washed with TBST and developed using the enhanced chemiluminescence
72 (ECL) reagent kit (Pierce) in Amersham Imager 680 machine. Images were then used to analyze the mean of
73 integrated densities of each blot using ImageJ software (National Institutes of Health, USA)(*73*).

74 *Immunohistochemistry (IHC) and CP-2-FITC incubation*

75 All staining was performed in paraformaldehyde (PFA)-fixed 30 μm thick sections of Dutch and wildtype
76 mouse brains. For A11 immunohistochemistry and cyclic D,L-α-peptide-2 (CP-2)-FITC fluorescence, free-
77 floating sections were washed with 0.1 M phosphate buffer saline (PBS) in 0.1% Triton (PBST) three times for
78 15 minutes and blocked with 2% bovine serum albumin (BSA) for 1 hour. Sections were incubated with a rabbit
79 polyclonal antibody A11, recognizing Aβ prefibrillar oligomers (1:2500) in antibody buffer (PBST containing 2%
80 BSA) overnight at 4°C. Sections were washed and incubated with Alexa Fluor 680 secondary goat anti-rabbit
81 antibody (1:1000 Abcam) in antibody buffer for 1 hour at room temperature. Sections were then incubated with
82 fluorescein-5-isothiocyanate (FITC)-conjugated CP-2 [0.15 mg/mL in 2% dimethyl sulfoxide (DMSO)] for 3
83 hours at room temperature. Sections were washed for 10 min in 1% PBST and kept for 15 min to dry. Sections
84 were then mounted on super frost glass slides, embedded with Fluro-Gel II mounting medium containing DAPI
85 (4',6-diamidino-2-phenylindole dihydrochloride) (Electron Microscopy Sciences, Hatfield PA), cover-slipped,
86 and stored in the dark for microscopic imaging. Immunofluorescence images containing the hippocampus, cortex,
87 and thalamus were obtained using the 20x objective of a Leica DM6000 microscope (Leica Microsystems,
88 Wetzlar, Germany), coupled to a controller module and a high sensitivity 3CCD video camera system (MBF

89 Biosciences, VT) and an Intel Xeon workstation (Intel). All images were analyzed by the Image J program(*73*),
90 and one section from each mouse (from a total of 5 mice in each group) were taken for analysis. The average
91 intensity was calculated from the area of the hippocampus, cortex, and thalamus.

92 *Brain tissue homogenization and Aβ ELISAs*

93 Fresh frozen brain tissue (cerebrum) was homogenized at a 1:5 tissue:buffer ratio, using a Precellys Evolution
94 homogenizer (Bertin Technologies**,** Montigny-Le-Bretonneux, France) to sequentially extract TBS, TBS with
95 0.5% Triton X-100 (TBS-T) and formic acid (FA) soluble fractions of Aβ. After homogenization in TBS, samples
96 were centrifuged at 16,000× *g* for 1 h at 4 °C (TBS_{16K}). For a subset of experiments, a fraction of this supernatant
97 was further centrifuged at 100,000× *g* followed by collection of the supernatant (TBS_{100K}). Homogenization of
98 the remaining tissue pellet was repeated according to the same procedure with TBS-T, then followed by FA. Brain
99 extracts were analyzed with Aβ1-40 and Aβ1-42 ELISAs, as previously described(*74*). In brief, 96-well half-area
00 plates were coated over night with 50 ng/well of anti-Aβ40 (custom production, Agrisera) or anti-Aβ42 (700254,
01 Thermo Fisher Scientific, USA), then blocked with 1% BSA in PBS for 3 h at RT. TBS_{16K}, TBS-T and FA brain
02 extracts were diluted in ELISA incubation buffer (PBS, 0.1% BSA, 0.05% Tween) and incubated over night at 4
03 °C, followed by detection with 0.5 µg/ml biotinylated 3D6 and HRP-conjugated streptavidin (Mabtech AB,
04 Nacka, Sweden). Signals were developed with K Blue Aqueous TMB substrate (Neogen Corp., Lexington, KA,
05 US). Plates were developed and read with a spectrophotometer at 450 nm. The TBS and TBS-T extracts were also
06 analyzed for soluble Aβ aggregates using two different sandwich ELISAs. The first, based on 3D6 as both capture
07 and detection antibody, allows for detection of Aβ aggregates from the size of a dimer, but not for monomeric Aβ.
08 The second preferentially detects larger soluble Aβ aggregates as it utilizes the Aβ protofibril selective antibody
09 mAb158 for capture and 3D6 for detection(*75*). Ninety-six-well half-area plates were coated over night with 3D6
10 (50 ng/well) and blocked with 1% BSA in PBS for 3 h at RT. Brain extracts were diluted in ELISA incubation
11 buffer (PBS, 0.1% BSA, 0.05% Tween) and incubated over night at 4 °C, followed by 3D6biotin detection and
12 development as above.

13 *Slice preparation, electrophysiological recordings, and analysis*

14 For electrophysiological experiments, hippocampi from 7- to 13-month-old Dutch and wildtype mice were
15 excised on ice and coronal hippocampal slices (400 µm) were cut with a tissue chopper. Slices were transferred
16 to a recording chamber where they were allowed to recover for 2 hours at 29°C and perfused with artificial
17 cerebrospinal fluid (ACSF) containing (124.0 mM), KCl (4.4 mM), Na_2HPO_4 (1.0 mM), $NaHCO_3$ (25.0 mM),
18 $CaCl_2$ (2.0 mM), $MgCl_2$ (2.0 mM), and glucose (10.0 mM). ACSF was bubbled with carbogen (95% O_2 and 5%
19 CO_2) and perfused at a flow rate of 2 ml/minute.

Field excitatory post-synaptic potentials (fEPSP) were measured after stimulating the Schaffer collateral fibers with a bipolar tungsten electrode placed at the CA3 and recording at the *stratum radiatum* of CA1 with a glass pipette filled with ACSF. Basal synaptic transmission was evaluated by plotting the relationship between increased voltages (5 V to 35 V) and evoked fEPSP responses, generating an input-output (I-O) curve. Recordings were measured at approximately 35% of the maximum evoked response as determined by the I-O curve. For LTP recordings, a 30-minute baseline was recorded prior to theta-burst stimulation (4 pulses at 100 Hz, with the bursts repeated at 5 Hz and 3 tetani of 10-burst trains administered at 15-second intervals), responses were recorded for 2 hours after tetanization and measured as fEPSP slope expressed as percentage of baseline. Paired-pulse facilitation (PPF) was induced by pairing two pulses at intervals of 15, 20, 30, 40, 50, 100, 200, 300, 500 and 1000 ms. PPF was expressed as the ratio between the second and the first fEPSP slopes. Post-tetanic potentiation (PTP) was induced by the above-described theta-burst stimulation protocol in presence of the NMDA receptor blocker D-APV (50 µM). Synaptic fatigue (SF) and replenishment were measured by 100 Hz stimulation followed by 7 stimuli spaced at 125 msec from each other in the presence of D-APV (50 µM).

Results were analyzed in pClamp 11 (Molecular Devices) and fEPSP slopes were compared by 2-way ANOVA for repeated measures for the I-O curve, LTP, PPF and PTP recordings. For statistical comparison of synaptic fatigue and replenishment, the rates of exponential growth/decay (k) extra sum-of-squares F test was used to test whether k differed between data sets vs. the data sets sharing one k-value. Statistics were performed using GraphPad Prism 9 software. Data were expressed as mean ± SEM. The level of significance was set at $p<0.05$.

Perfusions and tissue processing for electron microscopy and array tomography

For electron microscopy (EM) and array tomography synapse studies, 12-month-old Dutch and wildtype mice were anesthetized intraperitoneally, and transcardially perfused with 1% PFA in phosphate-buffered saline (PBS; pH 7.4) followed by 4% PFA with 0.125% glutaraldehyde in PBS as described previously(*24, 76, 77*). The brains were carefully removed, hemisected, postfixed overnight at 4°C in 4% PFA in PBS with 0.125% glutaraldehyde for synapse and immunogold analyses, or by 2% PFA with 2% glutaraldehyde in PBS for presynaptic vesicle analysis, and sectioned on a Vibratome (Leica VT1000S, Bannockburn, IL) into 250-µm thick sections. All sections were stored at 4°C in PBS with 0.1% sodium azide until use. Coronal sections encompassing the CA1 region of the hippocampus were prepared for EM as reported(*24, 77*). For synapse and immunogold analyses, slices were cryoprotected in graded phosphate buffer/glycerol washes at 4°C, and manually microdissected to obtain blocks containing the CA1 region. The blocks were rapidly freeze-plunged into liquid propane cooled by liquid nitrogen (-190°C) in a Universal cryofixation System KF80 (Reichert-Jung) and subsequently immersed in 1.5% uranyl acetate dissolved in anhydrous methanol at -90°C for 24 hours in a cryosubstitution unit (Leica). Block temperatures were raised from -90°C to -45°C in steps of 4°C/hour, washed with anhydrous methanol, and infiltrated with Lowicryl resin (Electron Microscopy Sciences) at -45°C. The resin was polymerized by exposure

53 to ultraviolet light (360 nm) for 48 hours at -45°C followed by 24 hours at 0°C. For presynaptic vesicle studies,
54 tissue blocks were washed overnight in 0.1 M sodium cacodylate buffer, placed in 1% tannic acid/0.1 M
55 cacodylate buffer solution at room temperature for one hour and washed 3 times for 10 minutes each in 0.1 M
56 sodium cacodylate. The samples were then incubated for 1 hour at room temperature in 2% osmium
57 tetroxide/double distilled water (ddH_2O), washed again in 0.1 M sodium cacodylate 3 times for 10 minutes then
58 subjected to a graduated ethanol dehydration series. After dehydration, the tissue samples were infiltrated with
59 Spurr Low Viscosity Embedding Kit (Sigma Aldrich) and polymerized for 12 hours at 70°C. For both EM
60 preparations, block faces were trimmed, ultrathin sections (90 nm) were cut with a diamond knife (Diatome) on
61 an ultramicrotome (Reichert-Jung), and sections were collected on formvar/carbon-coated nickel slot grids
62 (Electron Microscopy Sciences).

63 *Post-embedding immunogold labeling for EM*

64 Immuno-gold labeling was performed using a previously optimized method(*78*). Briefly, the EM sections were
65 treated with 0.1% sodium borohydride in 50 mM glycine prepared in Tris buffer for 6 minutes in the dark, to
66 remove aldehydes. Sections were then subjected to six quick rinses and two 10-minute washes in TBS. The
67 sections were incubated for 30 min in blocking buffer consisting of 2% human serum albumin (HSA) in TBS with
68 0.1% Triton X-100. After three short washes in TBS, the sections were incubated in anti-glutamate receptor 2 &
69 3 rabbit polyclonal antibody (Millipore AB1506, diluted 1:100 in 2% HSA in TBS) at room temperature overnight
70 with gentle shaking. Following six quick rinses and two 5-minute washes in TBS, the grids were incubated in
71 blocking buffer for 20 minutes, washed three times, and incubated for 90 minutes at room temperature in goat
72 anti-rabbit IgG conjugated to 10-nm gold particles (Aurion 25362), diluted 1:40 in 2% HSA and 5 mg/ml
73 polyethylene glycol in TBS. The grids were rinsed six times and washed for 5 minutes in TBS and then in
74 deionized water. Imaging was done using an H-7000 electron microscope (Hitachi High Technologies America,
75 Inc.) with an AMT Advantage CCD camera (Advanced Microscopy Techniques) at 15,000x. The electron
76 micrographs were adjusted for brightness and sharpness with Photoshop CS5 (Adobe Systems).

77 *Quantifying synapse density, ultrastructure, and distribution of immunogold particles at mGluR-2/3-labeled*
78 *synapses*

79 All EM analyses were conducted by an experimenter blinded to the genotypes of the mice. For synapse
80 quantification and ultrastructural analysis, nine sets of serial images across the same set of 5 consecutive ultrathin
81 sections were taken from the *stratum radiatum* of CA1 and imported into Adobe Photoshop (version CS5). To
82 obtain a stereologically unbiased population of synapses for quantitative morphologic analysis, we used a disector
83 approach on ultrathin sections as described(*24, 76, 77, 79*). Briefly, all axospinous synapses were identified within
84 the first and last 2 images of each 5-section serial set and counted if they were contained in the reference image

85 (layers 1 and 4) but not in the corresponding look-up image (layers 2 and 5). To increase sampling efficiency, the
86 reference image and look-up image were then reversed; thus, each animal included in the current study contributed
87 synapse density data from a total of 18 disector pairs. The total volume examined was 11.317 μm^3, and the height
88 of the disector was 180 nm. Axospinous synapse density (per μm^3) was calculated as the total number of counted
89 synapses from both images divided by the total volume of the disector. The criteria for inclusion as an axospinous
90 synapse included the presence of synaptic vesicles in the presynaptic terminal and a distinct asymmetric PSD
91 separated by a clear synaptic cleft. For a synapse to be scored as perforated it had to display two or more separate
92 PSDs.

93 To measure structural parameters such as spine head diameter and PSD length, we identified all axospinous
94 synapses in the middle portion of three serial sections. The synapse and spine head were followed through layers
95 2-5. In each layer, the PSD length (if present) and the spine head diameter at its widest point parallel to the synapse
96 were measured. PSD area was determined by summing the PSD lengths through all sections and multiplying by
97 section thickness (90 μm). This same process was repeated for unique synapses in layer 4 (reference layer 5),
98 following the synapses from layer 4 to layer 1. Each of these synapses were also classified as non-perforated or
99 perforated. A total of 734 total synapses (341 from Dutch mice and 393 from wildtype) were analyzed in this
00 manner. An average of 81 synapses per animal and a minimum of 71 synapses per animal were sampled. For each
01 unique synapse in layer 2 in each series (as identified for PSD length and spine head analysis above), the synapse
02 was followed through layers 2 though 5 and the number of immunogold particles in each of the following areas
03 were counted: active zone (presynaptic, within 45 nm of the membrane across from the PSD; region A), synaptic
04 cleft (region B), PSD (region C), peri-synaptic (peri—PSD, within 200 nm of the PSD on the post-synaptic spine
05 head; region D), postsynaptic membrane (>200 nm away from the PSD; region E), and postsynaptic cytoplasm
06 (region F). A cutoff of 45 nm away from the membrane was used to differentiate between receptors at the
07 membrane and receptors in the cytosol.

08 For presynaptic vesicle analysis, 100 synapses per animal were analyzed from at least 30 different images
09 taken at a magnification of 8,000x. PSD length, maximum spine head diameter, and cytosolic area of the
10 presynaptic terminal were measured using Adobe Photoshop 2023. Vesicles in the presynaptic terminal were
11 labeled with a dot in the center of the vesicle, and a line was drawn over the PSD. An algorithm was written in
12 Python that measured the shortest distance between each vesicle (represented by the dot in the center) and its
13 corresponding PSD (represented by the manually drawn line over the PSD) and reported a list of measurements
14 for all vesicles within an adjustable threshold distance (**Supplemental Figure 5**). For each synapse, the total
15 number of vesicles was determined with output from this algorithm, along with their individual distances from
16 the PSD. The vesicles were divided into bins of 10 and 50 nm for comparison of spatial distribution within the

presynaptic terminal. Additionally, vesicles within 10 nm of the PSD were classified as docked, based on a 17 nm average minimum diameter of vesicles in our samples(*80-82*).

ScRNA-seq and data analysis

For the scRNA-seq experiments, fresh hippocampi were dissected from 12- to 13-month-old Dutch and wildtype mice, and the tissue was dissociated into a single-cell suspension following the 10X Genomics sample preparation protocol. We pooled the hippocampi from 3 mice of the same gender, genotype, and age to reach the target concentration of 2000 cells/µl. The single cell cDNA libraries were generated using a V3 Chromium kit (10X Genomics) and sequenced using a NovaSeq S4 (Illumina).

The raw sequencing data were processed using the standard Cell Ranger pipeline to generate unique molecular identifier (UMI) count matrices. Starting from UMI matrices, we first performed quality control (QC) by removing low-quality cells with either too few (< 200) or too many (> 4000) genes detected, retaining 61,642 cells after filtering. We then removed insufficiently detected genes by keeping 20,548 genes expressed in more than one cell. After QC, we obtained 5,266 ~ 10,949 cells per individual, and an average of 618 unique genes per cell per individual. We performed a clustering analysis using a well-established scRNA-seq data integration workflow based on R package Seurat (v3)(*83*). Briefly, the UMIs data were first normalized by sequencing depth and log-transformed using the LogNormalize method implemented in Seurat. The 2,000 most variable gene features were identified, scaled, and centered. The scRNA-seq data across all sequencing libraries were combined based on the canonical correlation analysis (CCA) integration method available from Seurat. Next, dimensional reduction was performed using principal component analysis (PCA) based on the 2,000 most variable genes. The top 25 principal components (PCs) collectively explaining more than 90% of the variance were selected for calculating 2D dimensional reductions by Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP)(*84*). The same top 25 PCs were also used to compute the nearest neighbor graph and the subsequent cell clusters with the Louvain algorithm implemented in Seurat (*83*). This clustering analysis resulted in 14 clusters (named as Clusters 0 – 13, sorted by cluster size in a decreasing order) at a clustering resolution of 0.1. These clusters contained 267 to 20,702 cells each.

Cluster cell type annotation

For each cluster, we first interrogated the expression patterns of known gene markers to annotate clusters into major cell-types: inhibitory neurons (*Gad1*, *Gad2*), excitatory neurons (*Slc17a7*), astrocytes (*Aqp4*), oligodendrocytes (*Mog*), microglia (*Csf1r*, *Tyrobp,* and *Trem2*), oligodendrocyte progenitor cells (*Vcan* and *Pdgfra*), endothelial cells (*Flt1*), and pericytes (*Vtn* and *Pdgfrb*). Next, we calculated *de novo* cluster signatures by comparing the cells in a cluster against the cells of the other clusters using Wilcoxon rank sum test in Seurat. We defined cluster marker genes as those upregulated by at least 1.2-fold and with Bonferroni adjusted p-value less than 0.05. To assist the annotation of cell type of each cluster, we overlapped the *de novo* cluster marker gene

signatures with a large-scale collection of cell type markers curated from over 1,054 single-cell experiments(*85*), with p-value significance of the overlaps computed by a hypergeometric test.

Cluster-specific differential gene expression and functional enrichment analysis

DEGs between Dutch and wild type sample groups in each cluster were identified using MAST(*86, 87*) implemented in Seurat. Similarly, DEGs between males and females, and DEGs between Dutch and wild type in each sex group were identified using MAST. DEGs were determined at the cutoff of Bonferroni-corrected p-value ≤ 0.05. Functional enrichment of DEGs with MSigDB gene annotation collections was examined by a hypergeometric test. Results with Benjamini-Hochberg (BH) correction p-value ≤ 0.05 were considered statistically significant.

Microglia subclustering analysis

We studied a subset of microglial cells from the full data matrix. PCA was performed and then the top PCs collectively explaining more than 90% of the variance were selected for calculating dimensional reduction by UMAP (*84*) as well as for clustering analysis using Seurat (*83*). To test if the microglia subclusters represent known subtypes, we computed single cell signature scores (*88*) corresponding to homeostatic, disease-associated microglia (DAM), type I IFN-induced (IFN) and MHC-expressing (MHC) microglia based on signature genes curated by Chen and Colonna (*34*).

Quantifying presynaptic mitochondrial numbers and morphology

For analysis of mitochondria, 12 series of 9 consecutive 90-nm thick sections were selected from each mouse using a systematic-random approach for EM imaging. All mitochondrial analyses were performed by the same experimenter, blinded to the group designation of subjects as described (*89*). For each series of 9 consecutive sections, the middle fifth section was used as a reference, and all pre-synaptic axonal boutons containing a mitochondrion were identified. Each of these boutons was followed throughout the series, and the number, length and morphology of mitochondria were recorded. Mitochondria were classified as either straight or curved. Mitochondria that were bent at least 90° were identified as curved, while all other mitochondria were classified as straight.

Statistics

Data sets from the dot blot assays were analyzed using a one-way ANOVA followed by Tukey's multiple comparisons test. Data sets from the A11 immunohistochemistry and CP-2 cyclic peptide-FITC (CP-2-FITC) (*22*) fluorescence microscopy were analyzed using a two-way ANOVA followed by Sidak's multiple comparisons test. Data sets were analyzed using a two-tailed Student's t-test. Threshold for significance was set at $\alpha = 0.05$. Distribution of mGluR-2/3 immunogold particles was analyzed using repeated measures ANOVA. Data are

81 represented as mean ± SD. Statistical analyses were carried out using Prism software (version 9.2.0, GraphPad
82 Software, San Diego, CA).

83 *Data Availability*

84 The scRNA-seq data (cell ranger processed count matrices) are in a Synapse repository (accession
85 syn52752404, with direct link https://www.synapse.org/#!Synapse:syn52752404/files/).

86 **References**

87 1. S. W. Scheff, D. A. Price, F. A. Schmitt, S. T. DeKosky, E. J. Mufson. Synaptic alterations in CA1 in mild Alzheimer
88 disease and mild cognitive impairment. *Neurology* **68**, 1501-1508 (2007).
89 2. T. Arendt, Synaptic degeneration in Alzheimer's disease. *Acta Neuropathol* **118**, 167-179 (2009).
90 3. G. M. Shankar, D. M. Walsh. Alzheimer's disease: synaptic dysfunction and Abeta. *Mol Neurodegener* **4**, 48 (2009).
91 4. A. John, P. H. Reddy. Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and
92 mitochondria. *Ageing Res Rev* **65**, 101208 (2021).
93 5. M. Pang, L. Zhu, A. Gabelle, A. R. Gafson, R. W. Platt, J. E. Galvin, P. Krolak-Salmon, I. Rubino, C. de Moor, S.
94 Belachew, C. Shen. Effect of reduction in brain amyloid levels on change in cognitive and functional decline in
95 randomized clinical trials: An instrumental variable meta-analysis. *Alzheimers Dement*, (2022).
96 6. T. Bussiere, P. D. Friend, N. Sadeghi, B. Wicinski, G. I. Lin, C. Bouras, P. Giannakopoulos, N. K. Robakis, J. H.
97 Morrison, D. P. Perl, P. R. Hof. Stereologic assessment of the total cortical volume occupied by amyloid deposits
98 and its relationship with cognitive status in aging and Alzheimer's disease. *Neuroscience* **112**, 75-91 (2002).
99 7. A. Akram, D. Christoffel, A. B. Rocher, C. Bouras, E. Kovari, D. P. Perl, J. H. Morrison, F. R. Herrmann, V.
00 Haroutunian, P. Giannakopoulos, P. R. Hof. Stereologic estimates of total spinophilin-immunoreactive spine number
01 in area 9 and the CA1 field: relationship with the progression of Alzheimer's disease. *Neurobiol Aging* **29**, 1296-
02 1307 (2008).
03 8. P. T. Nelson, I. Alafuzoff, E. H. Bigio, C. Bouras, H. Braak, N. J. Cairns, R. J. Castellani, B. J. Crain, P. Davies,
04 K. Del Tredici, C. Duyckaerts, M. P. Frosch, V. Haroutunian, P. R. Hof, C. M. Hulette, B. T. Hyman, T. Iwatsubo,
05 K. A. Jellinger, G. A. Jicha, E. Kövari, W. A. Kukull, J. B. Leverenz, S. Love, I. R. Mackenzie, D. M. Mann, E.
06 Masliah, A. C. McKee, T. J. Montine, J. C. Morris, J. A. Schneider, J. A. Sonnen, D. R. Thal, J. Q. Trojanowski, J.
07 C. Troncoso, T. Wisniewski, R. L. Woltjer, T. G. Beach. Correlation of Alzheimer disease neuropathologic changes
08 with cognitive status: a review of the literature. *J Neuropathol Exp Neurol* **71**, 362-381 (2012).
09 9. K. Ishibashi, T. Tomiyama, K. Nishitsuji, M. Hara, H. Mori. Absence of synaptophysin near cortical neurons
10 containing oligomeric Abeta in Alzheimer's disease brain. *J Neurosci Res* **84**, 632-636 (2006).
11 10. M. P. Lambert, A. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. Morgan, I. Rozovsky, B.
12 Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft, W. L. Klein. Diffusible, nonfibrillar ligands
13 derived from Abeta1-42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci U S A* **95**, 6448-6453
14 (1998).
15 11. J. A. Fein, S. Sokolow, C. A. Miller, H. V. Vinters, F. Yang, G. M. Cole, K. H. Gylys. Co-localization of amyloid
16 beta and tau pathology in Alzheimer's disease synaptosomes. *Am J Pathol* **172**, 1683-1692 (2008).
17 12. S. Sokolow, K. M. Henkins, T. Bilousova, C. A. Miller, H. V. Vinters, W. Poon, G. M. Cole, K. H. Gylys. AD
18 synapses contain abundant Abeta monomer and multiple soluble oligomers, including a 56-kDa assembly.
19 *Neurobiol Aging* **33**, 1545-1555 (2012).
20 13. T. Bilousova, C. A. Miller, W. W. Poon, H. V. Vinters, M. Corrada, C. Kawas, E. Y. Hayden, D. B. Teplow, C. Glabe,
21 R. Albay, 3rd, G. M. Cole, E. Teng, K. H. Gylys. Synaptic Amyloid-beta Oligomers Precede p-Tau and Differentiate
22 High Pathology Control Cases. *Am J Pathol* **186**, 185-198 (2016).
23 14. D. M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. Rowan, D. J. Selkoe. Naturally
24 secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* **416**,
25 535-539 (2002).
26 15. G. M. Shankar, B. L. Bloodgood, M. Townsend, D. M. Walsh, D. J. Selkoe, B. L. Sabatini. Natural oligomers of the
27 Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-
28 dependent signaling pathway. *J Neurosci* **27**, 2866-2875 (2007).

16. J. P. Cleary, D. M. Walsh, J. J. Hofmeister, G. M. Shankar, M. A. Kuskowski, D. J. Selkoe, K. H. Ashe. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci* **8**, 79-84 (2005).
17. B. DaRocha-Souto, T. C. Scotton, M. Coma, A. Serrano-Pozo, T. Hashimoto, L. Sereno, M. Rodriguez, B. Sanchez, B. T. Hyman, T. Gomez-Isla. Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. *J Neuropathol Exp Neurol* **70**, 360-376 (2011).
18. S. Gandy, A. J. Simon, J. W. Steele, A. L. Lublin, J. J. Lah, L. C. Walker, A. I. Levey, G. A. Krafft, E. Levy, F. Checler, C. Glabe, W. B. Bilker, T. Abel, J. Schmeidler, M. E. Ehrlich. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. *Ann Neurol* **68**, 220-230 (2010).
19. E. Levy, M. D. Carman, I. J. Fernandez-Madrid, M. D. Power, I. Lieberburg, S. G. van Duinen, G. T. Bots, W. Luyendijk, B. Frangione. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. *Science* **248**, 1124-1126 (1990).
20. M. L. Maat-Schieman, S. G. van Duinen, J. Haan, R. A. Roos. Morphology of cerebral plaque-like lesions in hereditary cerebral hemorrhage with amyloidosis (Dutch). *Acta Neuropathol* **84**, 674-679 (1992).
21. E. M. Knight, S. H. Kim, J. C. Kottwitz, A. Hatami, R. Albay, A. Suzuki, A. Lublin, C. M. Alberini, W. L. Klein, P. Szabo, N. R. Relkin, M. Ehrlich, C. G. Glabe, S. Gandy, J. W. Steele. Effective anti-Alzheimer Abeta therapy involves depletion of specific Abeta oligomer subtypes. *Neurol Neuroimmunol Neuroinflamm* **3**, e237 (2016).
22. M. Habashi, S. Vutla, K. Tripathi, S. Senapati, P. S. Chauhan, A. Haviv-Chesner, M. Richman, S.-A. Mohand, V. Dumulon-Perreault, R. Mulamreddy, E. Okun, J. H. Chill, B. Guérin, W. D. Lubell, S. Rahimipour. Early diagnosis and treatment of Alzheimer's disease by targeting toxic soluble Aβ oligomers. *Proceedings of the National Academy of Sciences* **119**, e2210766119 (2022).
23. G. Kaur, M. Pawlik, S. E. Gandy, M. E. Ehrlich, J. F. Smiley, E. Levy. Lysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein. *Mol Psychiatry* **22**, 981-989 (2017).
24. K. A. Price, M. Varghese, A. Sowa, F. Yuk, H. Brautigam, M. E. Ehrlich, D. L. Dickstein,.Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-beta oligomers and no plaque pathology. *Mol Neurodegener* **9**, 41 (2014).
25. B. Readhead, J. V. Haure-Mirande, B. Zhang, V. Haroutunian, S. Gandy, E. E. Schadt, J. T. Dudley, M. E. Ehrlich. Molecular systems evaluation of oligomerogenic APP(E693Q) and fibrillogenic APP(KM670/671NL)/PSEN1(Deltaexon9) mouse models identifies shared features with human Alzheimer's brain molecular pathology. *Mol Psychiatry* **21**, 1153-1154 (2016).
26. S. Tucker, C. Möller, K. Tegerstedt, A. Lord, H. Laudon, J. Sjödahl, L. Söderberg, E. Spens, C. Sahlin, E. R. Waara, A. Satlin, P. Gellerfors, G. Osswald, L. Lannfelt. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. *J Alzheimers Dis* **43**, 575-588 (2015).
27. R. S. Zucker, W. G. J. A. r. o. p. Regehr. Short-term synaptic plasticity. **64**, 355-405 (2002).
28. H. Zhang, B. Gong, S. Liu, M. Fa, I. Ninan, A. Staniszewski, O. J. C. A. R. Arancio. Synaptic fatigue is more pronounced in the APP/PS1 transgenic mouse model of Alzheimer's disease. **2**, 137-140 (2005).
29. G. Yu, L.-G. Wang, Y. Han, Q.-Y. He, clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. *OMICS: A Journal of Integrative Biology* **16**, 284-287 (2012).
30. M. Ximerakis, S. L. Lipnick, B. T. Innes, S. K. Simmons, X. Adiconis, D. Dionne, B. A. Mayweather, L. Nguyen, Z. Niziolek, C. Ozek, V. L. Butty, R. Isserlin, S. M. Buchanan, S. S. Levine, A. Regev, G. D. Bader, J. Z. Levin, L. Rubin. Single-cell transcriptomic profiling of the aging mouse brain. *Nature Neuroscience* **22**, 1696-1708 (2019).
31. S. Krasemann, C. Madore, R. Cialic, C. Baufeld, N. Calcagno, R. El Fatimy, L. Beckers, E. O'Loughlin, Y. Xu, Z. Fanek, D. J. Greco, S. T. Smith, G. Tweet, Z. Humulock, T. Zrzavy, P. Conde-Sanroman, M. Gacias, Z. Weng, H. Chen, E. Tjon, F. Mazaheri, K. Hartmann, A. Madi, J. D. Ulrich, M. Glatzel, A. Worthmann, J. Heeren, B. Budnik, C. Lemere, T. Ikezu, F. L. Heppner, V. Litvak, D. M. Holtzman, H. Lassmann, H. L. Weiner, J. Ochando, C. Haass, O. Butovsky. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity* **47**, 566-581.e569 (2017).
32. G. D. Manocha, A. M. Floden, K. Rausch, J. A. Kulas, B. A. McGregor, L. Rojanathammanee, K. R. Puig, K. L. Puig, S. Karki, M. R. Nichols, D. C. Darland, J. E. Porter, C. K. Combs. APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease. *J Neurosci* **36**, 8471-8486 (2016).

33. H. Keren-Shaul, A. Spinrad, A. Weiner, O. Matcovitch-Natan, R. Dvir-Szternfeld, T. K. Ulland, E. David, K. Baruch, D. Lara-Astaiso, B. Toth, S. Itzkovitz, M. Colonna, M. Schwartz, I. Amit. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. *Cell* **169**, 1276-1290.e1217 (2017).
34. Y. Chen, M. Colonna. Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice? *J Exp Med* **218**, (2021).
35. S. Hong, V. F. Beja-Glasser, B. M. Nfonoyim, A. Frouin, S. Li, S. Ramakrishnan, K. M. Merry, Q. Shi, A. Rosenthal, B. A. Barres, C. A. Lemere, D. J. Selkoe, B. Stevens. Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* **352**, 712-716 (2016).
36. P. Sunderaraman, S. Cosentino, N. Schupf, J. Manly, Y. Gu, S. Barral. MEF2C Common Genetic Variation Is Associated With Different Aspects of Cognition in Non-Hispanic White and Caribbean Hispanic Non-demented Older Adults. *Front Genet* **12**, 642327 (2021).
37. J. C. Lambert, C. A. Ibrahim-Verbaas, D. Harold, A. C. Naj, R. Sims, C. Bellenguez, A. L. DeStafano, J. C. Bis, G. W. Beecham, B. Grenier-Boley, G. Russo, T. A. Thorton-Wells, N. Jones, A. V. Smith, V. Chouraki, C. Thomas, M. A. Ikram, D. Zelenika, B. N. Vardarajan, Y. Kamatani, C. F. Lin, A. Gerrish, H. Schmidt, B. Kunkle, M. L. Dunstan, A. Ruiz, M. T. Bihoreau, S. H. Choi, C. Reitz, F. Pasquier, C. Cruchaga, D. Craig, N. Amin, C. Berr, O. L. Lopez, P. L. De Jager, V. Deramecourt, J. A. Johnston, D. Evans, S. Lovestone, L. Letenneur, F. J. Morón, D. C. Rubinsztein, G. Eiriksdottir, K. Sleegers, A. M. Goate, N. Fiévet, M. W. Huentelman, M. Gill, K. Brown, M. I. Kamboh, L. Keller, P. Barberger-Gateau, B. McGuiness, E. B. Larson, R. Green, A. J. Myers, C. Dufouil, S. Todd, D. Wallon, S. Love, E. Rogaeva, J. Gallacher, P. St George-Hyslop, J. Clarimon, A. Lleo, A. Bayer, D. W. Tsuang, L. Yu, M. Tsolaki, P. Bossù, G. Spalletta, P. Proitsi, J. Collinge, S. Sorbi, F. Sanchez-Garcia, N. C. Fox, J. Hardy, M. C. Deniz Naranjo, P. Bosco, R. Clarke, C. Brayne, D. Galimberti, M. Mancuso, F. Matthews, S. Moebus, P. Mecocci, M. Del Zompo, W. Maier, H. Hampel, A. Pilotto, M. Bullido, F. Panza, P. Caffarra, B. Nacmias, J. R. Gilbert, M. Mayhaus, L. Lannefelt, H. Hakonarson, S. Pichler, M. M. Carrasquillo, M. Ingelsson, D. Beekly, V. Alvarez, F. Zou, O. Valladares, S. G. Younkin, E. Coto, K. L. Hamilton-Nelson, W. Gu, C. Razquin, P. Pastor, I. Mateo, M. J. Owen, K. M. Faber, P. V. Jonsson, O. Combarros, M. C. O'Donovan, L. B. Cantwell, H. Soininen, D. Blacker, S. Mead, T. H. Mosley, Jr., D. A. Bennett, T. B. Harris, L. Fratiglioni, C. Holmes, R. F. de Bruijn, P. Passmore, T. J. Montine, K. Bettens, J. I. Rotter, A. Brice, K. Morgan, T. M. Foroud, W. A. Kukull, D. Hannequin, J. F. Powell, M. A. Nalls, K. Ritchie, K. L. Lunetta, J. S. Kauwe, E. Boerwinkle, M. Riemenschneider, M. Boada, M. Hiltuenen, E. R. Martin, R. Schmidt, D. Rujescu, L. S. Wang, J. F. Dartigues, R. Mayeux, C. Tzourio, A. Hofman, M. M. Nöthen, C. Graff, B. M. Psaty, L. Jones, J. L. Haines, P. A. Holmans, M. Lathrop, M. A. PericakVance, L. J. Launer, L. A. Farrer, C. M. van Duijn, C. Van Broeckhoven, V. Moskvina, S. Seshadri, J. Williams, G. D. Schellenberg, P. Amouyel. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-1458 (2013).
38. M. Jang, E. Gould, J. Xu, E. J. Kim, J. H. Kim. Oligodendrocytes regulate presynaptic properties and neurotransmission through BDNF signaling in the mouse brainstem. *Elife* **8**, (2019).
39. C. Habermacher, M. C. Angulo, N. Benamer. Glutamate versus GABA in neuron-oligodendroglia communication. *Glia* **67**, 2092-2106 (2019).
40. K. Hoshi, H. Ito, E. Abe, T. J. Fuwa, M. Kanno, Y. Murakami, M. Abe, T. Murakami, A. Yoshihara, Y. Ugawa, T. Saito, T. C. Saido, K. Matsumoto, Y. Yamaguchi, K. Furukawa, H. Arai, M. Kanai, M. Miyajima, H. Arai, N. Ogawa, H. Akatsu, Y. Hashizume, H. Tateno, T. Honda, Y. Hashimoto. Transferrin Biosynthesized in the Brain Is a Novel Biomarker for Alzheimer's Disease. *Metabolites* **11**, (2021).
41. N. Lemon, E. Canepa, M. A. Ilies, S. Fossati. Carbonic Anhydrases as Potential Targets Against Neurovascular Unit Dysfunction in Alzheimer's Disease and Stroke. *Front Aging Neurosci* **13**, 772278 (2021).
42. X. Wang, B. E. Figueroa, I. G. Stavrovskaya, Y. Zhang, A. C. Sirianni, S. Zhu, A. L. Day, B. S. Kristal, R. M. Friedlander. Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. *Stroke* **40**, 1877-1885 (2009).
43. A. Lee, C. Kondapalli, D. M. Virga, T. L. Lewis, Jr., S. Y. Koo, A. Ashok, G. Mairet-Coello, S. Herzig, M. Foretz, B. Viollet, R. Shaw, A. Sproul, F. Polleux. Aβ42 oligomers trigger synaptic loss through CAMKK2-AMPKdependent effectors coordinating mitochondrial fission and mitophagy. *Nat Commun* **13**, 4444 (2022).
44. B. A. Györffy, V. Tóth, G. Török, P. Gulyássy, R. Kovács, H. Vadászi, A. Micsonai, M. E. Tóth, M. Sántha, L. Homolya, L. Drahos, G. Juhász, K. A. Kékesi, J. Kardos. Synaptic mitochondrial dysfunction and septin

accumulation are linked to complement-mediated synapse loss in an Alzheimer's disease animal model. *Cell Mol Life Sci* **77**, 5243-5258 (2020).

45. A. Norambuena, H. Wallrabe, R. Cao, D. B. Wang, A. Silva, Z. Svindrych, A. Periasamy, S. Hu, R. E. Tanzi, D. Y. Kim, G. S. Bloom, A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-β oligomers. *The EMBO Journal* **37**, e100241 (2018).
46. M. J. Calkins, M. Manczak, P. Mao, U. Shirendeb, P. H. Reddy. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. *Hum Mol Genet* **20**, 4515-4529 (2011).
47. J. S. da Silva, Y. Nonose, F. Rohden, P. C. Lukasewicz Ferreira, F. U. Fontella, A. Rocha, A. W. Brochier, R. V. Apel, T. M. de Lima, B. Seminotti, A. U. Amaral, A. Galina, D. O. Souza. Guanosine Neuroprotection of Presynaptic Mitochondrial Calcium Homeostasis in a Mouse Study with Amyloid-beta oligomers. *Mol Neurobiol* **57**, 4790-4809 (2020).
48. I. Klyubin, D. M. Walsh, W. K. Cullen, J. V. Fadeeva, R. Anwyl, D. J. Selkoe, M. J. Rowan. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. *Eur J Neurosci* **19**, 2839-2846 (2004).
49. R. Janz, T. C. Südhof, R. E. Hammer, V. Unni, S. A. Siegelbaum, V. Y. J. N. Bolshakov. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. **24**, 687-700 (1999).
50. W. Q. Zhao, F. Santini, R. Breese, D. Ross, X. D. Zhang, D. J. Stone, M. Ferrer, M. Townsend, A. L. Wolfe, M. A. Seager, G. G. Kinney, P. J. Shughrue, W. J. Ray. Inhibition of calcineurin-mediated endocytosis and alpha-amino3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. *J Biol Chem* **285**, 7619-7632 (2010).
51. N. R. Reinders, Y. Pao, M. C. Renner, C. M. da Silva-Matos, T. R. Lodder, R. Malinow, H. W. Kessels. Amyloidbeta effects on synapses and memory require AMPA receptor subunit GluA3. *Proc Natl Acad Sci U S A* **113**, E6526E6534 (2016).
52. M. D. Ikonomovic, R. Sheffield, D. M. Armstrong. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. *Hippocampus* **5**, 469-486 (1995).
53. T. L. Carter, R. A. Rissman, A. J. Mishizen-Eberz, B. B. Wolfe, R. L. Hamilton, S. Gandy, D. M. Armstrong. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage. *Exp Neurol* **187**, 299-309 (2004).
54. J. H. Y. Yeung, J. L. Walby, T. H. Palpagama, C. Turner, H. J. Waldvogel, R. L. M. Faull, A. Kwakowsky. Glutamatergic receptor expression changes in the Alzheimer's disease hippocampus and entorhinal cortex. *Brain Pathol* **31**, e13005 (2021).
55. B. G. Jang, S. In, B. Choi, M. J. Kim. Beta-amyloid oligomers induce early loss of presynaptic proteins in primary neurons by caspase-dependent and proteasome-dependent mechanisms. *Neuroreport* **25**, 1281-1288 (2014).
56. M. C. Herzig, D. T. Winkler, P. Burgermeister, M. Pfeifer, E. Kohler, S. D. Schmidt, S. Danner, D. Abramowski, C. Sturchler-Pierrat, K. Burki, S. G. van Duinen, M. L. Maat-Schieman, M. Staufenbiel, P. M. Mathews, M. Jucker. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. *Nat Neurosci* **7**, 954-960 (2004).
57. L. Grand Moursel, W. M. C. van Roon-Mom, S. M. Kiełbasa, H. Mei, H. P. J. Buermans, L. M. van der Graaf, K. M. Hettne, E. J. de Meijer, S. G. van Duinen, J. F. J. Laros, M. A. van Buchem, P. A. C. t Hoen, S. M. van der Maarel, L. van der Weerd. Brain Transcriptomic Analysis of Hereditary Cerebral Hemorrhage With Amyloidosis Dutch Type. *Front Aging Neurosci* **10**, 102 (2018).
58. R. A. Neff, M. Wang, S. Vatansever, L. Guo, C. Ming, Q. Wang, E. Wang, E. Horgusluoglu-Moloch, W.-m. Song, A. Li, E. L. Castranio, J. Tcw, L. Ho, A. Goate, V. Fossati, S. Noggle, S. Gandy, M. E. Ehrlich, P. Katsel, E. Schadt, D. Cai, K. J. Brennand, V. Haroutunian, B. Zhang. Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. *Science Advances* **7**, eabb5398 (2021).
59. A. Jishi, X. Qi, H. C. Miranda. Implications of mRNA translation dysregulation for neurological disorders. *Semin Cell Dev Biol* **114**, 11-19 (2021).
60. A. Ghosh, K. Mizuno, S. S. Tiwari, P. Proitsi, B. Gomez Perez-Nievas, E. Glennon, R. T. Martinez-Nunez, K. P. Giese. Alzheimer's disease-related dysregulation of mRNA translation causes key pathological features with ageing. *Translational Psychiatry* **10**, 192 (2020).

61. G. Joshi, Y. Chi, Z. Huang, Y. Wang. Aβ-induced Golgi fragmentation in Alzheimer's disease enhances Aβ production. *Proc Natl Acad Sci U S A* **111**, E1230-1239 (2014).
62. M. Calvo-Rodriguez, S. S. Hou, A. C. Snyder, E. K. Kharitonova, A. N. Russ, S. Das, Z. Fan, A. Muzikansky, M. Garcia-Alloza, A. Serrano-Pozo, E. Hudry, B. J. Bacskai. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease. *Nat Commun* **11**, 2146 (2020).
63. A.V. Venkataraman, A. Mansur, G. Rizzo, C. Bishop, Y. Lewis, E. Kocagoncu, A. Lingford-Hughes, M. Huiban, J. Passchier, J.B. Rowe, H. Tsukada, D. J. Brooks, L. Martarello, R. A. Comley, L. Chen, A.J. Schwarz, R. Hargreaves, R.N. Gunn, E. A. Rabiner, P. M. Matthew. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer's disease. *Sci Transl Med.* **14**(658), eabk1051. doi: 10.1126/scitranslmed.abk1051. (2022).
64. M. Balietti, B. Giorgetti, T. Casoli, M. Solazzi, F. Tamagnini, C. Burattini, G. Aicardi, P. Fattoretti. Early selective vulnerability of synapses and synaptic mitochondria in the hippocampal CA1 region of the Tg2576 mouse model of Alzheimer's disease. *J Alzheimers Dis* **34**, 887-896 (2013).
65. X. Wang, B. Su, H. G. Lee, X. Li, G. Perry, M. A. Smith, X. Zhu. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. *J Neurosci* **29**, 9090-9103 (2009).
66. C. D. Sanmartin, T. Adasme, C. Hidalgo, A. C. Paula-Lima. The antioxidant N-acetylcysteine prevents the mitochondrial fragmentation induced by soluble amyloid-beta peptide oligomers. *Neurodegener Dis* **10**, 34-37 (2012).
67. T. Umeda, T. Tomiyama, N. Sakama, S. Tanaka, M. P. Lambert, W. L. Klein, H. Mori. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. *J Neurosci Res* **89**, 1031-1042 (2011).
68. T. Umeda, E. M. Ramser, M. Yamashita, K. Nakajima, H. Mori, M. A. Silverman, T. Tomiyama. Intracellular amyloid β oligomers impair organelle transport and induce dendritic spine loss in primary neurons. *Acta Neuropathol Commun* **3**, 51 (2015).
69. L. Hedskog, C. M. Pinho, R. Filadi, A. Rönnbäck, L. Hertwig, B. Wiehager, P. Larssen, S. Gellhaar, A. Sandebring, M. Westerlund, C. Graff, B. Winblad, D. Galter, H. Behbahani, P. Pizzo, E. Glaser, M. Ankarcrona. Modulation of the endoplasmic reticulum–mitochondria interface in Alzheimer's disease and related models. *Proceedings of the National Academy of Sciences* **110**, 7916-7921 (2013).
70. C. H. van Dyck, C. J. Swanson, P. Aisen, R. J. Bateman, C. Chen, M. Gee, M. Kanekiyo, D. Li, L. Reyderman, S. Cohen, L. Froelich, S. Katayama, M. Sabbagh, B. Vellas, D. Watson, S. Dhadda, M. Irizarry, L. D. Kramer, T. Iwatsubo. Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*, (2022).
71. J.R. Sims, J.A. Zimmer, C.D. Evans, M. Lu, P. Ardayfio, J. Sparks, A.M. Wessels, S. Shcherbinin, H. Wang, E.S. Monkul Nery, E.C. Collins, P. Solomon, S. Salloway, L.G. Apostolova, O. Hansson, C. Ritchie, D.A. Brooks, M. Mintun, D.M. Skoyronsky; TRAILBLAZER-AL2 Investigators. Donanemab in Early Symptomatic Alzherimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. *JAMA.* **330**, 512-527. Doi: 10.001/jama.2023.13239 (2023).
72. H. Sun, Y. Wang, Y. Wang, F. Zeng. Case of Autosomal Dominant Alzheimer Disease With Negative Findings From PiB-PET Examination. *Neurol Genet* **10**, e200119 (2024).
73. C. A. Schneider, W. S. Rasband, K. W. Eliceiri. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* **9**, 671-675 (2012).
74. M. Pagnon de la Vega, V. Giedraitis, W. Michno, L. Kilander, G. Güner, M. Zielinski, M. Löwenmark, R. Brundin, T. Danfors, L. Söderberg, I. Alafuzoff, L. N. G. Nilsson, A. Erlandsson, D. Willbold, S. A. Müller, G. F. Schröder, J. Hanrieder, S. F. Lichtenthaler, L. Lannfelt, D. Sehlin, M. Ingelsson. The Uppsala APP deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation. *Sci Transl Med* **13**, (2021).
75. S. R. Meier, D. Sehlin, G. Hultqvist, S. Syvänen. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease. *Mol Imaging Biol* **23**, 665-675 (2021).
76. J. W. Steele, H. Brautigam, J. A. Short, A. Sowa, M. Shi, A. Yadav, C. M. Weaver, D. Westaway, P. E. Fraser, P. H. St George-Hyslop, S. Gandy, P. R. Hof, D. L. Dickstein. Early fear memory defects are associated with altered synaptic plasticity and molecular architecture in the TgCRND8 Alzheimer's disease mouse model. *J Comp Neurol* **522**, 2319-2335 (2014).

77. M. J. Lazarczyk, J. E. Kemmler, B. A. Eyford, J. A. Short, M. Varghese, A. Sowa, D. R. Dickstein, F. J. Yuk, R. Puri, K. E. Biron, M. Leist, W. A. Jefferies, D. L. Dickstein. Major Histocompatibility Complex class I proteins are critical for maintaining neuronal structural complexity in the aging brain. *Sci Rep* **6**, 26199 (2016).
78. Y. Hara, M. Punsoni, F. Yuk, C. S. Park, W. G. Janssen, P. R. Rapp, J. H. Morrison. Synaptic distributions of GluA2 and PKMzeta in the monkey dentate gyrus and their relationships with aging and memory. *J Neurosci* **32**, 73367344 (2012).
79. Y. Hara, C. S. Park, W. G. Janssen, M. T. Roberts, J. H. Morrison, P. R. Rapp. Synaptic correlates of memory and menopause in the hippocampal dentate gyrus in rhesus monkeys. *Neurobiol Aging* **33**, 421 e417-428 (2012).
80. Y. Han, P. S. Kaeser, T. C. Südhof, R. Schneggenburger. RIM determines Ca^{2+} channel density and vesicle docking at the presynaptic active zone. *Neuron* **69**, 304-316 (2011).
81. C. Tan, S. S. H. Wang, G. de Nola, P. S. Kaeser. Rebuilding essential active zone functions within a synapse. *Neuron* **110**, 1498-1515.e1498 (2022).
82. P. G. Camoletto, H. Vara, L. Morando, E. Connell, F. P. Marletto, M. Giustetto, M. Sassoè-Pognetto, P. P. Van Veldhoven, M. D. Ledesma. Synaptic vesicle docking: sphingosine regulates syntaxin1 interaction with Munc18. *PLoS One* **4**, e5310 (2009).
83. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nature Biotechnology* **36**, 411 (2018).
84. L. McInnes, J. Healy, J. Melville. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv* **1802.03426**, (2018).
85. O. Franzén, L.-M. Gan, J. L. M. Björkegren. PanglaoDB: a web server for exploration of mouse and human singlecell RNA sequencing data. *Database* **2019**, (2019).
86. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija. Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nature biotechnology* **36**, 411-420 (2018).
87. R. Satija, J. A. Farrell, D. Gennert, A. F. Schier, A. Regev. Spatial reconstruction of single-cell gene expression data. *Nat Biotechnol* **33**, 495-502 (2015).
88. C. Neftel, J. Laffy, M. G. Filbin, T. Hara, M. E. Shore, G. J. Rahme, A. R. Richman, D. Silverbush, M. L. Shaw, C. M. Hebert, J. Dewitt, S. Gritsch, E. M. Perez, L. N. Gonzalez Castro, X. Lan, N. Druck, C. Rodman, D. Dionne, A. Kaplan, M. S. Bertalan, J. Small, K. Pelton, S. Becker, D. Bonal, Q. D. Nguyen, R. L. Servis, J. M. Fung, R. Mylvaganam, L. Mayr, J. Gojo, C. Haberler, R. Geyeregger, T. Czech, I. Slavc, B. V. Nahed, W. T. Curry, B. S. Carter, H. Wakimoto, P. K. Brastianos, T. T. Batchelor, A. Stemmer-Rachamimov, M. Martinez-Lage, M. P. Frosch, I. Stamenkovic, N. Riggi, E. Rheinbay, M. Monje, O. Rozenblatt-Rosen, D. P. Cahill, A. P. Patel, T. Hunter, I. M. Verma, K. L. Ligon, D. N. Louis, A. Regev, B. E. Bernstein, I. Tirosh, M. L. Suva. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. *Cell* **178**, 835-849 e821 (2019).
89. Y. Hara, F. Yuk, R. Puri, W. G. Janssen, P. R. Rapp, J. H. Morrison. Presynaptic mitochondrial morphology in monkey prefrontal cortex correlates with working memory and is improved with estrogen treatment. *Proc Natl Acad Sci U S A* **111**, 486-491 (2014).
90. Y. He, P. R. Hof, W. G. M. Janssen, J. D. Rothstein, J. H. Morrison. Differential synaptic localization of GluR2 and EAAC1 in the macaque monkey entorhinal cortex: a postembedding immunogold study. *Neuroscience Letters* **311**, 161-164 (2001).
91. Y. Zhou, B. Zhou, L. Pache, M. Chang, A. H. Khodabakhshi, O. Tanaseichuk, C. Benner, S. K. Chanda. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat Commun* **10**, 1523 (2019).
92. K. D. Micheva, N. O'Rourke, B. Busse, S. J. Smith. Array tomography: high-resolution three-dimensional immunofluorescence. *Cold Spring Harb Protoc* **2010**, pdb top89 (2010).
93. K. D. Micheva, N. O'Rourke, B. Busse, S. J. Smith. Array tomography: imaging-stained arrays. *Cold Spring Harb Protoc* **2010**, pdb prot5526 (2010).
94. J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.-Y. Tinevez, D. J. White, V. Hartenstein, K. Eliceiri, P. Tomancak, A. Cardona. Fiji: an open-source platform for biological-image analysis. *Nature Methods* **9**, 676-682 (2012).
95. K. R. Kay, C. Smith, A. K. Wright, A. Serrano-Pozo, A. M. Pooler, R. Koffie, M. E. Bastin, T. H. Bak, S. Abrahams, K. J. Kopeikina, D. McGuone, M. P. Frosch, T. H. Gillingwater, B. T. Hyman, T. L. Spires-Jones. Studying synapses in human brain with array tomography and electron microscopy. *Nat Protoc* **8**, 1366-1380 (2013).

96. A. Cardona, S. Saalfeld, J. Schindelin, I. Arganda-Carreras, S. Preibisch, M. Longair, P. Tomancak, V. Hartenstein, R. J. Douglas. TrakEM2 software for neural circuit reconstruction. *PLoS One* **7**, e38011 (2012).
97. R. Kayed, E. Head, J. L. Thompson, T. M. McIntire, S. C. Milton, C. W. Cotman, C. G. Glabe, Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* **300**, 486-489 (2003).
98. R. Kayed, E. Head, F. Sarsoza, T. Saing, C.W. Cotman, M. Necula, L. Margol, J. Wu, L. Breydo, J.L. Thompson, S. Rasool, T. Gurlo, P. Butler, C.G. Glabe. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener.* **2**, 18. doi: 10.1186/1750-1326-2-18 (2007).
99. M. Richman, S. Wilk, M. Chemerovski, S.K. Wärmländer, A. Wahlström, A. Gräslund, S. Rahimipour. *In vitro* and mechanistic studies of an antiamyloidogenic self- assembled cyclic D, L-α-peptide architecture. *J Am Chem Soc.* **135**, 3474-84 (2016).
100. M. Chemerovski-Glikman, M. Richman, S. Rahimipour. Structure-based study of antiamyloidogenic cyclic D,L-α-peptides. *Tetrahedron* **70**, 7639–7644 (2014).
101. M. Chemerovski-Glikman, E. Rozentur-Shkop, M. Richman, A. Grupi, A. Getler, H. Y. Cohen, H. Shaked, C. Wallin, S. K. Wärmländer, E. Haas, A. Gräslund, J. H. Chill, S. Rahimipour. Self-assembled cyclic D,L-alpha-peptides as generic conformational inhibitors of the alpha-synuclein aggregation and toxicity: In vitro and mechanistic studies. *Chemistry*, ***22***, 14236-14246 (2016).
102. A. Belostozky, M. Richman, E. Lisniansky, A. Tovchygrechko , J. Chill, S. Rahimipour. Inhibition of tau-derived hexapeptide aggregation and toxicity by a self-assembled cyclic d,l-α-peptide conformational inhibitor. *Chem Commun (Camb).* **54**, 5980-5983. doi: 10.1039/c8cc01233d (2018).
103. K. Ono, M.M. Condron, D. B. Teplow. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. *Proc. Natl. Acad. Sci. U. S. A.* **106,** 14745-14750 (2009).
104. R.J. Rodenburg. Biochemical diagnosis of mitochondrial disorders. *J Inherit Metab Dis* **34**,283-92 (2011).
105. T.L. Emmerzaal, R.J. Rodenburg, H. Tanila, V. Verweij, A.J. Kiliaan, T. Kozicz T. Age-Dependent Decrease of Mitochondrial Complex II Activity in a Familial Mouse Model for Alzheimer's Disease. *J Alzheimers Dis.* **66**, 75-82. doi: 10.3233/JAD-180337 (2018).
106. M. Noguchi-Shinohara, K. Shuta, H. Murakami, Y. Mori, J. Komatsu, C. Kobayashi, S. Hersch, K. Horie, K. Ono. Lecanemab-Associated Amyloid-β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease. *Ann Neurol.* doi: 10.1002/ana.27175. (2025).
107. D. Shea, E. Colasurdo, A. Smith, C. Paschall, S. Jayadev, C.D. Keene, D. Galasko, A. Ko, G. Li, E. Peskind, V. SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. *Proc Natl Acad Sci U S A.* **119**: e2213157119. doi: 10.1073/pnas.2213157119 (2022).
108. Choi, E.H., Kim, M.H., Park, S.J. Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. *International journal of molecular sciences*, 25(14), p.7952. 109 (2024).
109. Xu, J., Du, W., Zhao, Y., Lim, K., Lu, L., Zhang, C., Li, L. Mitochondria targeting drugs for neurodegenerative diseases—Design, mechanism and application. *Acta Pharmaceutica Sinica B*, 12(6), pp.2778-2789, (2022).
110. E. Andersson, N. Lindblom, S. Janelidze, G. Salvadó, E. Gkanatsiou, L. Söderberg, C. Möller, L. Lannfelt, J. Ge, J. Hanrieder, K. Blennow, T. Deierborg, N. Mattsson-Carlgren, H. Zetterberg, G. Gouras, O. Hansson. Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF $A\beta_{42}/A\beta_{40}$ ratios, neurofilament light and tau in Alzheimer's disease model mice. *Nat Aging*. doi: 10.1038/s43587-025-00810-8. (2025).

Acknowledgments

We would like to thank all the members of the Dickstein, Arancio, Levy, Rahimipour, Lubell, Guerin, and Ehrlich/Gandy laboratories, and William G. M. Janssen, Allison Sowa, Daniel R. Dickstein, Frank Yuk, and Michael Ragusa for technical assistance and discussion. The authors would like to thank Yanzhuang Wang (Shenzhen Bay Laboratory), and Gary Gibson, Giovanni Manfredi, and Csaba Konrad (all from Weill Cornell Medical College) for valuable conversations and suggestions. We also thank Tamas Kozicz and Graeme Preston (Icahn School of Medicine at Mount Sinai) for performing the electron transport chain activity assays.

Funding:

National Institutes of Health grant F32AG077900 (ELC)
National Institutes of Health grant P30 AG066514 to Mary Sano with Developmental Pilot Award (ELC, SG)
National Institutes of Health grant U01AG046170 (SG, MEE, MW, BZ)
National Institutes of Health grant RF1AG058469 (SG, MEE)
National Institutes of Health grant RF1AG059319 (SG, MEE)
National Institutes of Health grant R01AG061894 (SG, MEE)
Cure Alzheimer's Fund (SG, MEE, SR, BG, WL)
National Institutes of Health grant RF1AG057440 (MW, BZ)
National Institutes of Health grant RFIAG056507 (CG)
National Institutes of Health grant AG056732 (EL)
National Institutes of Health grant R01NS110024 (OA)
Alzheimer's Association NIRG-12-242386 (DLD)
Medical Student Training in Aging Research Program Scientific Fellowship from the American Federation for Aging Research (EB)
The Linda Wachner Foundation (SG, MEE)
National Institutes of Health grant RF1AG077828 (MW)
National Institutes of Health grant R21AG077168 (MW)
Alzheimer's Association AARG-22-928419 (MW)

Author contributions:

Conceptualization: MEE, SG, EL, DLD, OA
Methodology: EB, MV, DLD, KT, SH, JVDL, OA, EA, ELC, CDS, MW, BZ, CG, SR
Investigation: RT, MV, DL, EB, DLD, FG, ELC, KT, SH, JVDL, OA, EA, HZ, BZ, MW, CDS, LS, LL, MI, SR
Visualization: MV, DLD, KT, SH, ELC, MW
Supervision: MEE, SG, EL, DLD, OA
Writing—original draft: MV, DLD, EB, ELC, SG, EA, OA, MW
Writing—review & editing: MV, DLD, ELC, SG, MEE, EL, CG, SR, WL, BG

Competing interests: Dr. Gandy is a co-founder of Recuerdo Pharmaceuticals. He has served as a consultant in the past for J&J, Diagenic, and Pfizer, and he currently consults for Cognito Therapeutics, GLG Group, SVB Securities, Guidepoint, Third Bridge, MEDACORP, Altpep, Vigil Neurosciences, Memory Garden, and Eisai. He has received research support in the past from Warner-Lambert, Pfizer, Baxter, and Avid. The authors declare no other competing interests.

Data and materials availability: The scRNA-seq data (cell ranger processed count matrices) are in a Synapse repository (accession syn52752404, with direct link https://www.synapse.org/#!Synapse:syn52752404/files/). All data are available in the main text or the supplementary materials." The APP^{E693Q} transgenic mouse can be provided by Thomas Jefferson University pending scientific review and a completed material transfer agreement. Requests for the APP^{E693Q} transgenic mouse should be submitted to michelle.ehrlich@mssm.edu.

71 **Disclaimer**

72 The opinions expressed herein are those of the authors and are not necessarily representative of those of the
73 government of the United States, the Uniformed Services University of the Health Sciences, the Department of
74 Defense (DoD), or the United States Army, Navy or Air Force or the Henry M. Jackson Foundation for the
75 Advancement of Military Medicine, Inc.

Supplementary Materials Table of Contents

Supplementary Methods
Figs. S1 to S15
References (92 to 110)

76 **Figure Captions**

77 **Figure 1. Aging-related accumulation of NFA-Aβ in the cerebral cortex of APP^{E693Q} transgenic mice**
78 **revealed by double labeling with A11 epitomic immunohistochemistry and CP-2 cyclic peptide-FITC**
79 **fluorescence microscopy.** Representative images from 24-month-old Dutch mice showing fluorescence
80 microscopy using DAPI, A11 staining with AlexaFluor-680 secondary antibody (red), and CP-2 cyclic
81 peptideFITC (CP-2-FITC, green)(*22*). Lower right panel is a merge of A11 and CP-2-FITC images. Scale bar =
82 100 µm. Quantification of A11-immunoreactive and CP-2-FITC-immunoreactive NFA-Aβ aggregates in 2- and
83 24mo Dutch shown in Figure S1C. ** $p < 0.01$.

84

85 **Figure 2. Dutch mice do not exhibit impairment in basal synaptic transmission or LTP. (A, B)** Basal
86 neurotransmission **(A)** and LTP **(B)** are unimpaired in hippocampal slices from Dutch mice as compared to
87 slices from wildtype littermates at the age of 7 to 7.5 months ($F_{(1,28)}$ =0.0026, p=0.959 and $F_{(1,28)}$ =0.219,
88 p=0.644, respectively). **(C-D)** Slices from Dutch mice do not exhibit impairment of basal neurotransmission **(C)**
89 and LTP **(D)** at the age of 10.5 to 11 months compared to wildtype mice ($F_{(1,18)}$ =0.116, p=0.737 and $F_{(1,18)}$
90 =0.017, =0.899, respectively).

91

92 **Figure 3. Distribution and ultrastructure of mGluR-2/3-labeled synapses were comparable in the CA1 of**
93 **12-monthold Dutch and wildtype mice.** mGluR-2/3-labeled synapses were defined as having ≥1 immunogold
94 particle located in the PSD or synaptic cleft. **(A-C)** No significant differences were observed between Dutch and
95 wildtype mice in percentage of mGluR-2/3-labeled total, perforated, and non-perforated synapses, respectively.
96 **(D-F)** Average PSD area of mGluR-2/3labeled synapses for all synapses, non-perforated synapses, and perforated
97 synapses, respectively. Dutch mice had larger PSD area of mGluR-2/3-labeled non-perforated synapses than
98 wildtype (p= 0.04, by unpaired t test), whereas perforated synapses or total synapses were comparable between
99 the two groups. **(G-I)** No significant difference was observed in density of immuno-gold particles in mGluR-2/3-
00 labeled synapses, calculated as number of immuno-gold particles/ PSD area, for all synapses, non-perforated
01 synapses, and perforated synapses, respectively. Data are mean ± SD from n = 5 wildtype, and n = 4 Dutch mice.

02

03 **Figure 4. Dutch mice showed impairment of certain measurements of short-term synaptic plasticity.**
04 **(A)** Dutch mice showed no impairment in paired-pulse facilitation at the age of 11 to 13 months old ($F_{(1, 220)}$
05 =0.06364, p=0.8011; 2-way ANOVA). **(B)** Post-tetanic potentiation was significantly reduced in slices from 11-
06 to 13-month-old Dutch mice compared to wildtype ($F_{(1,36)}$ =4.771, p=0.036; 2-way ANOVA for the first 6 points
07 after potentiation). **(C)** Significant differences were observed in synaptic fatigue when comparing slices from
08 Dutch mice and wildtype littermates (k=2.247±0.1622 for wildtype and k=2.782±0.1634 for Dutch, p=0.015, k:

rate of exponential decay). **(D)** The rate of synaptic vesicle replenishment following a 100 Hz stimulation was found to be significantly increased in hippocampal slices from Dutch mice as compared to slices from wildtype littermates (k=7.509±0.7277 for wildtype, k=13.64±1.682 for Dutch, $p<0.0001$, k: rate of exponential growth).

Figure 5. Synaptic distribution of mGluR-2/3 in the CA1 is comparable in 12-month-old wildtype and Dutch mice. (A-C) Examples of mGluR-2/3 immuno-gold staining. Note the distribution of immuno-gold particles within the presynaptic terminal (purple masks) and the postsynaptic dendritic spine (cyan masks). Scale bars = 500 nm. **(D)** Schematic diagram demonstrating the 6 synaptic bins used to categorize the localization of each gold particle (adapted from (*90*)). Bin A, active zone (presynaptic, within 45 nm of the membrane across from the PSD); B, synaptic cleft; C, postsynaptic density (PSD); D, peri-synaptic (Peri-PSD, on the postsynaptic spine head, within 200 nm of the PSD); E, postsynaptic membrane (>200 nm away from the PSD) and F, postsynaptic cytoplasm (cytosol). **(E)** Distribution of immuno-gold labeled mGluR-2/3 among the various regions of the synapse showed no significant differences between wildtype and Dutch mice. Data are mean ± SD from wildtype (n = 5) and Dutch (n = 4) (repeated measures ANOVA).

Figure 6. Transcriptional responses in Dutch mouse brains. (A) scRNA-seq of hippocampal tissues from 12-month-old male and female Dutch and wildtype mice (n=2 samples per sex per genotype with 3 mice pooled per sample). UMAP plot showing 14 distinguishable clusters (0-13). **(B)** Violin plots illustrating expression of marker genes for each cell type. **(C)** UpSet plot highlighting the overlapping and unique genes between the clusters. **(D)** Bar plot showing number of DEGs per cluster by directionality.

Figure 7. Overlapping transcriptomic profiles highlight processes impacted in multiple cell types. (A) Dot plot highlighting shared GO term enrichment across clusters. **(B-C)** Dot plot of genes associated with shared GO terms **(B)** "structural constituent of ribosome" and **(C)** "amyloid-beta binding", split into Dutch and wildtype mice across all clusters. Wildtype mice are in blue, Dutch mice are in purple. **(D)** UpSet plot comparing overlap of cluster DEGs (adj. p-value <0.05) with previously defined aging gene list. **(E)** Heatmap of log2FC of genes shared with aging gene list.

Figure 8. Microglia transcriptomic profiles are similar between Dutch and wildtype mice. (A) UMAP plot showing sub-clustering analysis results for Cluster 2 microglia, identifying 3 subpopulations of microglia with UMAP plot split by genotype to the right. **(B)** UMAP plots showing expression of previously identified microglial signatures; DAM(*33*), homeostatic, IFN and MHC(*34*). **(C)** Violin plots showing expression across subclusters by genotypes of selected homeostatic microglial genes.

42

43 **Figure 9. Transcriptional profile of Cluster 6 excitatory neurons is altered in Dutch mice. (A)** Volcano plot
44 of genes enriched in Cluster 6 as calculated by pseudobulk differential expression analysis. Red genes are Log2FC
45 > 0.25 and adj. p-value < 0.05, blue Log2FC < 0.25 and adj. p-value < 0.05, green genes are Log2FC > 0.25 and
46 adj. p-value > 0.05, and grey genes are Log2FC < 0.25 and adj. p-value > 0.05. **(B-C)** GO term analysis of **(B)**
47 upregulated and **(C)** downregulated genes enriched in Cluster 6 (adj. p-value < 0.05) using metascape(*91*). **(D)**
48 Dot plot of DEGs unique to Cluster 6.

49

50 **Figure 10. Fewer mitochondria were present in presynaptic boutons at excitatory synapses in the CA1 of**
51 **12-month-old Dutch mice compared to wildtype**. **(A)** Electron micrographs showing representative examples
52 of presynaptic mitochondria (blue masks). **(B)** Curved presynaptic mitochondria demonstrate a bend of at least
53 90°. Straight presynaptic mitochondria did not exhibit any curvature. Scale bar = 500 nm. **(C)** Total number, **(D)**
54 number of straight mitochondria, **(E)** number of curved mitochondria, **(F)** percentage of curved mitochondria,
55 **(G)** average diameter, and **(H)** number of layers traversed by each mitochondrion in wildtype and Dutch mice.
56 Data are mean ± SD from n = 4 wildtype and n = 5 Dutch mice.

57

58 **Supplementary Tables Titles and Captions**

59 **Supplementary Table 1. Cluster Cell Numbers.** Number of cells per cluster per sample.

60 **Supplementary Table 2. Cluster Markers.** De novo cluster signatures calculated by comparing cell clusters
61 using Wilcox rank sum test in Seurat.

62 **Supplementary Table 3. Cluster DEGs.** Differentially expressed genes across all 14 clusters using MAST
63 implemented in Seurat.

64 **Supplementary Table 4. Cluster 6 GO-terms.** GO-term analysis of genes enriched in Cluster 6 (l2f>0, padj
65 <0.05) using metascape.

66 **Supplementary Table 5. Cluster 6 GO-terms.** GO-term analysis of genes enriched in Cluster 6 (l2f<0, padj
67 <0.05) using metascape.

68 **Supplementary Table 6. Cluster 4 GO-terms.** GO-term analysis of genes enriched in Cluster 6 (l2f>0, padj
69 <0.05) using metascape.

70 **Supplementary Table 7. Ligand-Receptor Pairs for Clusters 6 and 4.** Cell-cell communication analysis
71 calculated by Cellphone DB to compute interaction between Clusters 6 and Clusters 9 based on known Ligand-
72 Receptor pairs. t-test was used to compare interaction strength differences between Dutch and WT mice

73 **Supplementary Table 8. Mitochondrial electron transport chain (mETC) enzymology. mETC complexes**
74 **standardized to μg protein.**

75 **Supplementary Table 9. Mitochondrial electron transport chain (mETC) enzymology. mETC complexes**
76 **standardized to mU/ml citrate synthase.**

77

78



076 **Figure Captions**

077 **Figure 1. Aging-related accumulation of NFA-Aβ in the cerebral cortex of APP^{E693Q} transgenic mice**
078 **revealed by double labeling with A11 epitomic immunohistochemistry and CP-2 cyclic peptide-FITC**
079 **fluorescence microscopy.** Representative images from 24-month-old Dutch mice showing fluorescence
080 microscopy using DAPI, A11 staining with AlexaFluor-680 secondary antibody (red), and CP-2 cyclic
081 peptideFITC (CP-2-FITC, green)(*22*). Lower right panel is a merge of A11 and CP-2-FITC images. Scale bar =
082 100 µm. Quantification of A11-immunoreactive and CP-2-FITC-immunoreactive NFA-Aβ aggregates in 2- and
083 24mo Dutch shown in Figure S1C. ** $p < 0.01$.

084
085



086 **Figure 2. Dutch mice do not exhibit impairment in basal synaptic transmission or LTP. (A, B)** Basal
087 neurotransmission **(A)** and LTP **(B)** are unimpaired in hippocampal slices from Dutch mice as compared to
088 slices from wildtype littermates at the age of 7 to 7.5 months ($F_{(1,28)}$ =0.0026, p=0.959 and $F_{(1,28)}$ =0.219,
089 p=0.644, respectively). **(C-D)** Slices from Dutch mice do not exhibit impairment of basal neurotransmission **(C)**
090 and LTP **(D)** at the age of 10.5 to 11 months compared to wildtype mice ($F_{(1,18)}$ =0.116, p=0.737 and $F_{(1,18)}$
091 =0.017, =0.899, respectively).



Figure 3. Distribution and ultrastructure of mGluR-2/3-labeled synapses were comparable in the CA1 of 12-monthold Dutch and wildtype mice. mGluR-2/3-labeled synapses were defined as having ≥1 immunogold particle located in the PSD or synaptic cleft. **(A-C)** No significant differences were observed between Dutch and wildtype mice in percentage of mGluR-2/3-labeled total, perforated, and non-perforated synapses, respectively. **(D-F)** Average PSD area of mGluR-2/3labeled synapses for all synapses, non-perforated synapses, and perforated synapses, respectively. Dutch mice had larger PSD area of mGluR-2/3-labeled non-perforated synapses than wildtype (p= 0.04, by unpaired t test), whereas perforated synapses or total synapses were comparable between the two groups. **(G-I)** No significant difference was observed in density of immuno-gold particles in mGluR-2/3-labeled synapses, calculated as number of immuno-gold particles/ PSD area, for all synapses, non-perforated synapses, and perforated synapses, respectively. Data are mean ± SD from n = 5 wildtype, and n = 4 Dutch mice.



Figure 4. Dutch mice showed impairment of certain measurements of short-term synaptic plasticity. **(A)** Dutch mice showed no impairment in paired-pulse facilitation at the age of 11 to 13 months old ($F_{(1, 220)}$ =0.06364, p=0.8011; 2-way ANOVA). **(B)** Post-tetanic potentiation was significantly reduced in slices from 11- to 13-month-old Dutch mice compared to wildtype ($F_{(1,36)}$ =4.771, p=0.036; 2-way ANOVA for the first 6 points after potentiation). **(C)** Significant differences were observed in synaptic fatigue when comparing slices from Dutch mice and wildtype littermates (k=2.247±0.1622 for wildtype and k=2.782±0.1634 for Dutch, p=0.015, k: rate of exponential decay). **(D)** The rate of synaptic vesicle replenishment following a 100 Hz stimulation was found to be significantly increased in hippocampal slices from Dutch mice as compared to slices from wildtype littermates (k=7.509±0.7277 for wildtype, k=13.64±1.682 for Dutch, p<0.0001, k: rate of exponential growth).



Figure 5. Synaptic distribution of mGluR-2/3 in the CA1 is comparable in 12-month-old wildtype and Dutch mice. (A-C) Examples of mGluR-2/3 immuno-gold staining. Note the distribution of immuno-gold particles within the presynaptic terminal (purple masks) and the postsynaptic dendritic spine (cyan masks). Scale bars = 500 nm. **(D)** Schematic diagram demonstrating the 6 synaptic bins used to categorize the localization of each gold particle (adapted from (*90*)). Bin A, active zone (presynaptic, within 45 nm of the membrane across from the PSD); B, synaptic cleft; C, postsynaptic density (PSD); D, peri-synaptic (Peri-PSD, on the postsynaptic spine head, within 200 nm of the PSD); E, postsynaptic membrane (>200 nm away from the PSD) and F, postsynaptic cytoplasm (cytosol). **(E)** Distribution of immuno-gold labeled mGluR-2/3 among the various regions of the synapse showed no significant differences between wildtype and Dutch mice. Data are mean ± SD from wildtype (n = 5) and Dutch (n = 4) (repeated measures ANOVA).



Figure 6. Transcriptional responses in Dutch mouse brains. (A) scRNA-seq of hippocampal tissues from 12-month-old male and female Dutch and wildtype mice (n=2 samples per sex per genotype with 3 mice pooled per sample). UMAP plot showing 14 distinguishable clusters (0-13). **(B)** Violin plots illustrating expression of marker genes for each cell type. **(C)** UpSet plot highlighting the overlapping and unique genes between the clusters. **(D)** Bar plot showing number of DEGs per cluster by directionality.



Figure 7. Overlapping transcriptomic profiles highlight processes impacted in multiple cell types. (A) Dot plot highlighting shared GO term enrichment across clusters. **(B-C)** Dot plot of genes associated with shared GO terms **(B)** "structural constituent of ribosome" and **(C)** "amyloid-beta binding", split into Dutch and wildtype mice across all clusters. Wildtype mice are in blue, Dutch mice are in purple. **(D)** UpSet plot comparing overlap of cluster DEGs (adj. p-value <0.05) with previously defined aging gene list. **(E)** Heatmap of log2FC of genes shared with aging gene list.



Figure 8. Microglia transcriptomic profiles are similar between Dutch and wildtype mice. (A) UMAP plot showing sub-clustering analysis results for Cluster 2 microglia, identifying 3 subpopulations of microglia with UMAP plot split by genotype to the right. **(B)** UMAP plots showing expression of previously identified microglial signatures; DAM(*33*), homeostatic, IFN and MHC(*34*). **(C)** Violin plots showing expression across subclusters by genotypes of selected homeostatic microglial genes.



Figure 9. Transcriptional profile of Cluster 6 excitatory neurons is altered in Dutch mice. (A) Volcano plot of genes enriched in Cluster 6 as calculated by pseudobulk differential expression analysis. Red genes are Log2FC > 0.25 and adj. p-value < 0.05, blue Log2FC < 0.25 and adj. p-value < 0.05, green genes are Log2FC > 0.25 and adj. p-value > 0.05, and grey genes are Log2FC < 0.25 and adj. p-value > 0.05. **(B-C)** GO term analysis of **(B)** upregulated and **(C)** downregulated genes enriched in Cluster 6 (adj. p-value < 0.05) using metascape(*91*). **(D)** Dot plot of DEGs unique to Cluster 6.



Figure 10. Fewer mitochondria were present in presynaptic boutons at excitatory synapses in the CA1 of 12-month-old Dutch mice compared to wildtype. **(A)** Electron micrographs showing representative examples of presynaptic mitochondria (blue masks). **(B)** Curved presynaptic mitochondria demonstrate a bend of at least 90°. Straight presynaptic mitochondria did not exhibit any curvature. Scale bar = 500 nm. **(C)** Total number, **(D)** number of straight mitochondria, **(E)** number of curved mitochondria, **(F)** percentage of curved mitochondria, **(G)** average diameter, and **(H)** number of layers traversed by each mitochondrion in wildtype and Dutch mice. Data are mean ± SD from n = 4 wildtype and n = 5 Dutch mice.